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Diagnostic and clinical value of routine polymerase chain reaction analysis of 
intraocular fluid specimens in the diagnosis of suspected infectious posterior 
uveitis 
Scheepers MA, Lecuona KA, Rogers G, Bunce C, Corcoran C, Michaelides M 
Groote Schuur Hospital Ophthalmology, Cape Town, South Africa 
Objective: To assess the diagnostic and clinical value of routinely performing 
polymerase chain reaction (PCR) analysis on intraocular fluid samples in patients with 
suspected infectious posterior uveitis in a population with a high prevalence of human 
immunodeficiency virus infection.
Design: Retrospective, interventional consecutive case series of 159 patients 
presenting with suspected active infectious posterior uveitis.
Methods: Patients presenting with a first episode of suspected infectious posterior 
uveitis underwent PCR testing of ocular fluid samples in a tertiary care hospital over a 
five year period. PCR analysis was performed for cytomegalovirus (CMV), varicella 
zoster virus (VZV), herpes simplex virus type 1 and 2 (HSV), toxoplasma gondii (TG) 
and mycobacterium tuberculosis (MTB). 
Results: The prevalence of the commonest causes of infectious posterior uveitis based 
on PCR studies was CMV in 47% of patients, VZV in 11% and TG in 10%. HSV was not 
identified. PCR analysis confirmed the initial clinical diagnosis in 55 patients (35%) and 










PCR testing was non specific (uncertain) in 51 patients (32%), with PCR providing a 
definitive final diagnosis in 20 of these patients (39%); necrotizing herpetic retinopathy
and ocular toxoplasmosis were particularly difficult to diagnose correctly without the use 
of PCR analysis. The overall PCR sensitivity was 84%, specificity was 99%, positive 
predictive value was 97% and negative predictive value was 95%.
Conclusion: The clinical phenotype alone was unreliable in diagnosing the underlying 
infectious cause in a quarter of patients in this study. Since the outcome of incorrectly 
treated infective uveitis can be blinding, PCR analysis of ocular fluids is recommended 
early in the disease even in resource poor settings.
Financial disclosure(s): The authors have no proprietary or commercial interest in any 
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1.0 Introduction 
This study aims to assess the usefulness of performing a vitreous biopsy or anterior 
chamber tap of ocular fluids for polymerase chain reaction (PCR) analysis in patients 
presenting clinically with suspected infectious posterior uveitis at Groote Schuur 
Hospital in Cape Town, South Africa.  
Infectious uveitis occurs commonly in South Africa, especially in those patients who 
are immune compromised. It is a potentially devastating disease which often results 
in loss of vision, and treatment can help prevent further destruction of eye tissues. 
Knowing the causative organism is important because it allows the institution of early 
appropriate treatment to prevent complications and spread of infection.  
The identification of the aetiological pathogens responsible for infectious posterior 
uveitis has historically been based on clinical presentation. Since the advent of PCR 
tests for common infectious agents, PCR analysis has become a useful adjunct in 
determining the organism responsible.
In posterior uveitis caused by Cytomegalovirus, Herpes Simplex virus and Varicella 
Zoster virus, PCR analysis has reported sensitivities greater than 90% and 
specificities greater than 95%1. Toxoplasma gondii posterior uveitis PCR analysis 
has reported sensitivities of 40 – 60%.2
The sensitivity of PCR analysis in the diagnosis of Mycobacterium Tuberculosis 
posterior uveitis is undetermined at present. 
The usefulness of PCR in clinical practice has not previously been investigated.
2.0 Study objective 
The primary objective is to determine how useful PCR is in establishing an 
aetiological diagnosis in patients with suspected infectious posterior uveitis, seen at 
the uveitis clinic at Groote Schuur Hospital.
3.0 Study design 
Retrospective case review. 
4.0 Study population 
All patients suffering from a first episode of suspected infectious posterior uveitis not 
previously investigated, presenting between May 2004 and June 2009 at the Groote 
Schuur Hospital Eye clinic in Cape Town. 
4.1 Inclusion criteria 
Patients presenting with active, or inactive(“old”) chorioretinitis or a choroidal 
granuloma over a five year period from May 2004 to June 2009 who had PCR 
analysis of either vitreous or anterior chamber ocular fluid. PCR analysis was 
performed for common causative organisms namely Cytomegalovirus (CMV), Herpes 
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Mycobacterium Tuberculosis (TB). Tests for CMV, HSV, VZV, and Toxoplasma 
Gondii were performed commonly whereas TB tests were performed less commonly. 
Patients who had a poor retinal view from posterior synaechiae or media opacity, and 
who were suspected to have infectious posterior uveitis will be included in the study. 
4.2 Exclusion criteria 
1. Previous episodes of chorioretinitis.
2. Absence of chorioretinitis on fundoscopy if the retina was visible.
5.0 Material and methods 
5.1 Patient recruitment 
A list of all patients who had ocular fluid PCR analysis over a five year period from 
May 2004 to June 2009 was obtained from the virology laboratory at Groote Schuur 
Hospital.  
Patient folders will be requested from medical records and the Ophthalmology case 
notes will be reviewed by 2 Ophthalmologists in order to complete data sheets with 
the required patient information (Please see Appendix 1).
5.2 Vitreous biopsy procedure according to standard department protocol 
Vitreous biopsies are performed under local anaesthesia using a 23 gauge needle 
under sterile conditions in a minor operation theatre in the out-patient department or 
in main operation theatre. Anterior chamber samples are obtained under sterile 
conditions using either a 28 gauge or 30 gauge half inch needles depending on 
availability.
5.3 Study aims 
5.3.1 The primary aim of the study is to determine the proportion of cases in which 
PCR confirmed, altered or did not contribute to making a final aetiological diagnosis.  
5.3.2 To determine whether there is a statistically significant difference in the PCR 
positive rate between vitreous and anterior chamber aspirates.  
5.3.3 To look for features associated with a positive PCR result, including anterior 
chamber inflammation, vitritis, relative afferent pupil defect, and time from onset of 
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6.0 Statistical analysis 
6.1 Statistical analysis will be performed by Catey Bunce from the Moorfields Eye 
Hospital Statistics and Research department. 
7.0 Ethical and regulatory considerations 
Ethical approval to be obtained by the Groote Schuur Hospital research committee. 
7.0 References 
1. Van Gelder RN. CME review: Polymerase chain reaction diagnostics for posterior
segment disease. Retina 2003;23:445–452.
2. Fardeau C, Romand S, Rao NA, et al. Diagnosis of toxoplasmic retinochoroiditis 
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Literature review 1 
Objectives of literature review: 2 
1. To explore the current knowledge of the causes of infectious posterior uveitis in a 3 
population with a high prevalence of human immunodeficiency virus 4 
2. To document current diagnostic methods used in establishing an aetiological diagnosis 5 
in infectious posterior uveitis 6 
3. To compare the value of different diagnostic techniques currently used to determine 7 
the aetiology of infectious posterior uveitis, in particular the value of polymerase chain 8 
reaction (PCR) analysis of intraocular fluid.  9 
4. To explore the effect of different intraocular fluid sampling sites on PCR test accuracy 	  10 
Literature search strategy: 11 
a. An online pubmed search was performed using the following search words. 12 
1. Diagnosis AND posterior uveitis OR chorioretinitis OR uveitis OR cytomegalovirus 13 
OR herpes simplex virus OR varicella zoster virus OR toxoplasma gondii OR 14 
toxoplasmosis OR mycobacterium tuberculosis OR syphilis. 15 
2. Polymerase chain reaction analysis AND posterior uveitis OR chorioretinitis OR 16 
uveitis OR cytomegalovirus OR herpes simplex virus OR varicella zoster virus OR 17 
toxoplasma gondii OR toxoplasmosis OR mycobacterium tuberculosis OR syphilis. 18 
b. Reference lists from pubmed cited articles were cross referenced 19 
c. The South African Department of Health online database was searched for human 20 
immunodeficiency virus prevalence statistics, which are based on antenatal clinic data.   21 
All pubmed cited articles relevant to infectious posterior uveitis and its diagnosis were 22 
included in the literature search.  23 
The search was limited to papers published in English 24 
Quality criteria: 25 














In high income countries, uveitis affects approximately 200 per 100,000 in the population, 28 
and uveitis and its complications accounts for up to 35% of severe visual impairment.1  In 29 
low income countries, uveitis and it’s complications are thought to be even more 30 
common, affecting an estimated 714 per 100,000 and contributing to 25% of blindness.1  31 
Posterior uveitis is thought to comprise approximately 5% of all uveitis entities.2 The 32 
commonest pathogens responsible for infectious posterior uveitis and panuveitis are 33 
Herpes Simplex Virus (HSV) type 1 and 2, Varicella-Zoster Virus (VZV), Cytomegalovirus 34 
(CMV), Toxoplasma Gondii (TG), Treponema Pallidum and Mycobacterium Tuberculosis 35 
(MTB).2 In high income countries, the most common infectious aetiologies are TG, HSV, 36 
and VZV, whereas CMV is a common pathogen in countries with a high prevalence of 37 
human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS).3-5 38 
Blindness and visual impairment caused by infectious uveitis can be prevented by early 39 
identification of the correct aetiological pathogen responsible for infectious uveitis, and 40 
the prompt administration of specific antimicrobial therapy.6 This is particularly so in 41 
immunocompromised patients.3,6 42 
The etiological diagnosis of infectious uveitis is initially made on the clinical features of 43 
the phenotypic expression of the disease, but there is often significant overlap between 44 
the phenotypic expressions of these different pathogens.7 Simultaneous infection of the 45 
retina with multiple agents in patients with AIDS has been reported, making it almost 46 
impossible to make a correct clinical diagnosis.8 Establishing a diagnosis based on 47 
clinical findings alone is also difficult in cases where media opacity or poor pupil dilation 48 
may mask clinical features. Under these circumstances an incorrect diagnostic decision 49 
not only causes a delay of appropriate treatment and prevention of loss of vision, but also 50 














DIAGNOSTIC METHODS USED IN ESTABLISHING AN ETIOLOGICAL DIAGNOSIS IN 53 
INFECTIOUS POSTERIOR UVEITIS 54 
 55 
a. Peripheral blood analysis 56 
Analysis of peripheral blood samples to detect antigens and antibodies is of limited value 57 
in most cases. This is because peripheral blood analysis does not necessarily reflect 58 
disease activity in the eye.  59 
Positive serological results may be incidental, especially if the prevalence of a particular 60 
infection is high in a given population.3,6 Negative serological results make the chances of 61 
an infection less likely, but cannot rule out the possibility of that infection.10 62 
Peripheral blood analysis to determine the aetiology of infectious uveitis is thus not very 63 
useful in most cases. 64 
 65 
b. Intraocular fluid analysis 66 
1. Culture of intraocular fluids  67 
Culturing pathogens which commonly cause uveitis is a difficult task in many cases.11-14 68 
Viruses are obligatory intracellular pathogens, and they therefore require susceptible host 69 
cells in order to culture. Many susceptible specific viral strain host cells are not available 70 
for the purpose of culturing and as a result there are many viruses we are unable to 71 
culture.  Fungi and bacteria are generally easier to culture than viruses, although some 72 
bacteria and fungi have specific nutritional requirements making them more challenging 73 
to culture (for example mycobacterium tuberculosis & treponema pallidum.)15 74 
Pathogenic load in sampled ocular fluid is important, as low pathogenic load results in a 75 
lower sensitivity. Pathogens that are liberated into the ocular humours as part of the 76 
disease process are usually easier to culture. 77 
Another consideration is the stability of the pathogen in transit from clinic to the 78 













to testing can affect culture sensitivity. Specialised diagnostic laboratories are not 80 
available at all health care facilities, and thus transporting samples to laboratories can 81 
result in considerable time delay before culturing is initiated. This is important for viral 82 
culture, as some viruses are unstable in cell free environments, and the infectious viral 83 
load may drop considerably from sampling time to culture time.  84 
Results from culturing take longer than PCR or antigen / antibody analysis, and this is 85 
unfavourable, as rapid diagnoses are required.  86 
 87 
2. Intraocular antibody analysis 88 
The detection of intraocular antibodies to a particular pathogen may indicate possible 89 
intraocular infection, but as the blood ocular barrier is often broken down in uveitis, 90 
immunoglobulins may cross from the peripheral blood to the intraocular fluid. Infection 91 
elsewhere in the body causing antibody production may thus lead to a false positive 92 
result. 93 
 94 
3. Goldman Witmer Coefficient 95 
Testing for antibodies is more useful if the levels of intraocular antibody are compared to 96 
that of peripheral blood serum antibody production.  97 
The Goldman Witmer coefficient (GWC) corrects for the leakage of immunoglobulins from 98 
the peripheral blood into intraocular fluid. The GWC compares the ratio of specific 99 
antibody in the eye and peripheral blood, to the ratio of total IgG in the eye and peripheral 100 
blood. The formula is: (Specific IgG in aqueous / specific IgG in serum) / (Total IgG in 101 
aqueous / Total IgG in serum). When leakage occurs, division of the ratios approximate 102 
one.6,16-17 A Goldman Witmer coefficient of greater than 3 is generally considered 103 
positive, and therefore indicative of probable intraocular infection.10,16-18 104 
False positives may however result from polyclonal B-Cell activation by certain 105 













polyclonal B Cell activation may be missed. Testing for antibodies against two pathogens 107 
and calculating the C’ coefficient comparing specific aqueous / serum ratios can help one 108 
identify polyclonal B cell activation, but one has to consider the rare possibility of multiple 109 
infections.10,19 110 
False negatives may occur when high serum antibodies combined with extensive blood 111 
aqueous barrier breakdown may mask a positive coefficient. 10,18  112 
GWC has been described for the most common causes of posterior uveitis including 113 
Toxoplasma gondii, CMV, HSV, VZV, Rubella Virus and Toxocara canis.3,6,20-21 114 
 115 
4. Polymerase chain reaction (PCR) analysis 116 
PCR is a technique whereby a single or a few copies of a piece of DNA are amplified 117 
across several orders of magnitude, generating millions of copies of a particular nucleic 118 
acid sequence. Several different PCR techniques are available, all of which provide 119 
different advantageous additional information.  120 
Quantitative real time polymerase chain reaction is used to amplify and simultaneously 121 
quantify a targeted nucleic acid sequence. For one or more specific sequences in a DNA 122 
sample, real time PCR enables both detection and quantification. The quantity can be 123 
either an absolute number of copies or a relative amount when normalized to DNA input 124 
or additional normalizing genes. Real time PCR is thus able to provide information 125 
regarding viral loads.22 Real time PCR has been used to measure viral loads and disease 126 
activity in patients with herpetic uveitis as well as CMV retinitis.23-25 127 
Multiplex PCR uses multiple, unique primer sets within a single PCR reaction to produce 128 
amplicons of varying sizes specific to different DNA sequences, i.e. different transgenes. 129 
By targeting multiple genes at once, additional information may be gained from a single 130 














Nested polymerase chain reaction is a modification of the polymerase chain reaction 133 
intended to reduce the contamination in products due to the amplification of unexpected 134 
primer binding sites. Nested polymerase chain reaction involves two sets of primers, 135 
used in two successive runs of polymerase chain reaction, the second set intended to 136 
amplify a secondary target within the first run product. Nested PCR has been shown to 137 
be useful in the diagnosis of ocular Mycobacterium Tuberculosis.27 138 
False positives PCR results are however possible if contamination occurs, or if 139 
pathogens enter the eye from the peripheral blood, but are not causing any active 140 
infection in the eye.28-29 141 
False negative results may occur in cases of low specimen antigenic load or 142 
polymorphism (genetic variability or mutation).29 143 
PCR analysis of intraocular fluid to detect viral infection in infectious posterior uveitis has 144 
been shown to be a sensitive and highly specific test. From previous studies, PCR CMV 145 
retinitis sensitivities range from 91% to 95% and for VZV or HSV causing necrotizing 146 
herpetic retinopathy sensitivities range from 79% to 100%. 6,30-34  147 
PCR analysis in patients with ocular toxoplasmosis is generally less sensitive than viral 148 
retinitis. Studies have shown variable sensitivity ranging from 27% to 85%.6,20,35-39 149 
PCR procedures are generally more sensitive than cultures and allow more rapid 150 
detection.  151 
Although the identification of the pathogens responsible for infectious posterior uveitis 152 
has historically been based on clinical presentation, the advent of PCR tests for common 153 
infectious agents has become a useful adjunct in determining the organism responsible. 154 
De Boer and colleagues showed that in patients with AIDS & CMV retinitis, polymerase 155 
chain reaction analysis is preferable above local antibody production in detecting the 156 
inciting agent of retinitis. In cases of Toxoplasma chorioretinitis, the combination of both 157 













showed that in Acute Retinal Necrosis the PCR sensitivity was higher at 2 weeks after 159 
the onset of disease compared to an acute sample. (81% versus 100%; n = 16)6 160 
PCR is very useful in cases of media opacity where the retina isn’t visible.  161 
 162 
COMPARISON OF DIFFERENT DIAGNOSTIC TECHNIQUES CURRENTLY USED TO 163 
DETERMINE THE AETIOLOGY OF COMMON INFECTIOUS POSTERIOR UVEITIS 164 
SYNDROMES 165 
 166 
As mentioned before, some of the most common pathogens responsible for infectious 167 
posterior uveitis and panuveitis include Cytomegalovirus (CMV), Varicella-Zoster Virus 168 
(VZV), Herpes Simplex Virus (HSV) type 1 and 2, Toxoplasma Gondii, Treponema 169 
Pallidum and Mycobacterium Tuberculosis.2 170 
 171 
CMV retinitis (CMVR) 172 
CMV retinitis usually affects patients who are immune compromised. CMV retinitis is the 173 
most common cause of acquired viral retinitis, primarily because of the acquired 174 
immunodeficiency syndrome (AIDS).40 175 
Ocular CMV most commonly presents as a viral necrotizing retinitis, which typically starts 176 
in the mid-periphery and can progress in a “brush fire” pattern.41 CMV retinitis may also 177 
present as an indolent type CMV retinitis that presents with atrophic central lesions with 178 
granular whitish active borders.42 179 
Before the advent of PCR, the diagnosis of CMV retinitis relied predominantly on fundal 180 
appearance. In the early stages of disease and in patients with atypical features, it can 181 
be difficult to differentiate between retinitis caused by CMV, and retinitis associated with 182 
the other herpes viruses. Discrimination between viral and non-viral pathogens such as 183 
Toxoplasma gondii can be particularly difficult by clinical examination alone as their 184 













and the prompt initiation of appropriate therapy is essential both for the preservation of 186 
sight and the improved survival of the patient. Furthermore, the personal cost to the 187 
patient and the waste of resources associated with the use of multiple antibiotic and 188 
antiviral therapies prompts the need for rapid, sensitive, and specific diagnostic tests for 189 
ocular pathogens such as CMV.43 190 
In AIDS patients, the clinical diagnosis of CMV retinitis can be even more difficult if 191 
multiple agents are co-infecting the retina, which underlines the importance of intraocular 192 
fluid analysis.44 193 
Many studies have showed both PCR and GWC to be useful in confirming the diagnosis 194 
of CMV retinitis. There are however no large-scale concurrent studies on PCR and GWC. 195 
PCR for CMV retinitis has been shown to be up to 95 % sensitive in detecting untreated 196 
CMV retinitis and 48% sensitive in detecting CMV retinitis that had been treated with 197 
systemic gancyclovir or foscarnet, or both.30 PCR for CMV retinitis is highly sensitive for 198 
untreated CMV retinitis, and also highly specific. 199 
 200 
Necrotising herpetic retinitis  201 
The necrotizing herpetic retinopathies, induced by viruses of the herpes family (HSV, 202 
VZV and CMV), includes acute retinal necrosis (ARN) and progressive outer retinal 203 
necrosis (PORN).45 204 
Necrotizing herpetic retinitis is a continuous spectrum of diseases induced by herpes 205 
viruses, whose clinical expression depends on the immune state of the host, presenting 206 
as classical ARN at one end in patients with non-detectable or slight immune dysfunction, 207 
to PORN in severely immunosuppressed patients at the other end, and with intermediary 208 
forms between these extremes.45  209 
ARN was first described by Urayama in 1971 and was termed Kirisawa uveitis.46 ARN is 210 













choroidal vasculature  (2) a confluent, necrotizing retinitis that preferentially affects the 212 
peripheral retina, and (3) a moderate to severe vitritis.47 213 
PORN was first described by Forster and colleagues in 1990. They described two 214 
patients with unilateral fulminant retinal necrosis involving the outer retinal layers with 215 
sparing of the inner retina and retinal vasculature.48 In 1994 Engstrom and colleagues 216 
reported on thirty-eight patients (65 eyes) with PORN.49 They noted that all their patients 217 
suffered from the acquired immune deficiency syndrome and that the median CD4 218 
lymphocyte count was 21/mm3. A history of cutaneous zoster infection was documented 219 
in 67% of patients, and anterior chamber reaction and vitreous inflammatory reactions 220 
were absent or minimal in all patients. They also noted typical retinal lesions to be 221 
multifocal, deep opacities scattered in the retinal periphery, and 32% of eyes had 222 
macular involvement at presentation. 223 
VZV is the most frequent cause of ARN. HSV is the second most common cause of ARN. 224 
HSV associated ARN occurs more commonly with meningo-encephalitis than VZV 225 
associated ARN.50,51 226 
However, the typical phenotype of necrotizing herpetic retinitis may also be caused by 227 
treponema pallidum (syphilis), toxoplasma gondii and CMV.9,31,52-53 It is therefore 228 
important to establish a laboratory based identification of the pathogen. 229 
Polymerase chain reaction based assays of ocular fluid samples are often used for the 230 
diagnosis of acute retinal necrosis syndrome, and to determine the specific pathogen 231 
causing the syndrome.6,31,54-56 The sensitivity of PCR for HSV and VZV is in excess of 232 
90% and the specificity exceeds 95%.31,33,57 233 
 234 
The results for PCR analysis is highly sensitive and specific, as demonstrated by 235 
Pendergast, who found zero false positives for Herpes DNA in 75 intraocular specimens 236 
(35 aqueous and 40 vitreous samples) from 75 patients undergoing scleral buckling or 237 













VZV and EBV. Of the 75 samples tested, none were found to be PCR positive. This was 239 
despite the percentage of patients with positive herpes virus serology ranging from 86% 240 
to 100%.58 241 
The false-negative rate is however difficult to determine because it is usually compared 242 
with cultures, and viral cultures are among the least efficient diagnostic tests for 243 
intraocular fluid. In the case of infectious uveitis, the final clinical diagnosis is therefore 244 
used as gold standard.59 For this reason, validation in consecutive patients typical of 245 
those who usually undergo the testing is needed to assess the usefulness of the method 246 
for routine diagnostic use.  247 
In cases where acute retinal necrosis is due to Toxoplasma Gondii, GWC determination 248 
in addition to PCR is particularly useful in establishing a diagnosing. 249 
 250 
Toxoplasma Gondii related posterior uveitis 251 
Ocular toxoplasmosis (OT) caused by the parasite toxoplasma gondii is a common cause 252 
of posterior uveitis that can be contracted congenitally or through postnatal infection.60 253 
OT may arise from a primary infection or reactivation. 254 
OT most frequently presents as a unilateral focal retinochoroidal lesion.61-62 OT may 255 
however have varied atypical phenotypic expressions, particularly in 256 
immunocompromised patients, where OT lesions may be multifocal, or where OT may 257 
present as diffuse areas of retinal necrosis mimicking ARN.53,62-63 It may thus be very 258 
difficult to determine the most likely etiological pathogen based on clinical appearance 259 
alone, and diagnostic testing is most valuable in these situations. 260 
There is a high prevalence of TG antibody seropositivity in the general population in 261 
Southern Africa, as many adults have had infection with T. Gondii.64 Peripheral blood 262 














GWC analysis for TG has been shown to be one of the most sensitive tests for T Gondii. 265 
(Up to 93% positive results) PCR analysis of intraocular fluid is another useful test to 266 
detect T. Gondii. In primary OT PCR & GWC analysis appear to contribute equally to the 267 
diagnosis.3,20-21,62  268 
PCR appears to be particularly valuable in cases of atypical OT in immunocompromised 269 
patients.6,62 Improved PCR techniques such as qualitative multiplex PCR used by Sugita 270 
and colleagues have also improved sensitivities.39 271 
Van Gelder noted that vitreous PCR might be more sensitive than aqueous PCR due to 272 
the size of the TG organism and the paucity of the organism.29 Fekkar noted the 273 
combination of GWC & PCR to increase diagnostic sensitivity to 93% in a study of 34 274 
patients with OT.35 275 
Early in the disease process viral nucleic acids are easi r to determine, whereas late in 276 
the disease process PCR positive rates are lower and GWC positive rates are higher as 277 
antibodies are being produced.6 278 
 279 
Mycobacterium tuberculosis induced posterior uveitis 280 
The reported incidence of ocular tuberculosis among patients with systemic tuberculosis 281 
varies from 1.46% to 18%, and is increasing in areas with a high HIV / AIDS 282 
prevalence.65-70 283 
Posterior segment involvement in immunocompetent individuals may manifest a 284 
spectrum of clinical manifestations, from mild nummular focal and multifocal choroiditis to 285 
severe endogenous endophthalmitis. The overlying vitreous may have little or no vitreous 286 
cells.  Multifocal choroidal tubercles, which are foci of granuloma in the choroid, 287 
frequently occur with involvement of the retina. These tuberculomas appear to reach the 288 
choroid via a haematogenous spread. The choroidal tubercles appear to be bilateral or 289 
unilateral and measure between 0.2 and 3 mm. Although they appear commonly in the 290 













frequently involved and sometimes serous detachment may occur.  Retinal vasculitis may 292 
occur in the absence of choroiditis or retinitis. This form of predominant phlebitis 293 
occurring in patients with healed tuberculosis may represent an immune-mediated 294 
reaction to tuberculoprotein. Rapid progression of the disorder and even more varied 295 
presentations may occur in immunocompromised individuals.71 296 
Serpiginous choroiditis like chorioretinal lesions may also be observed. Tuberculous 297 
serpiginous-like choroiditis often presents with significant vitritis, and lesions are usually 298 
multifocal in the posterior pole and periphery, whereas true serpiginous choroiditis most 299 
often reveals minimal vitritis and frequently shows bilateral involvement with larger 300 
solitary lesions extending primarily from the juxtapapillary area and sparing the 301 
periphery.72 Optic nerve papillitis and juxtapapillary chorioretinitis may occur as well.73 302 
Ocular TB is a great mimicker, and hence may give rise to varied presentations. 303 
 304 
Initial diagnosis may involve performing a mantoux tuberculin skin test, a chest x ray and 305 
sputum analysis for acid fast bacilli / culture. As most patients in South Africa are 306 
immunized with the Bacillus Calmette-Guerin strain vaccine, false positive results are 307 
common although the false positive rates due to BCG vaccination are unknown. The 308 
interferon-gamma release assays (IGRAs) such as the commercially available T SPOT-309 
TB and the QuantiFERON-TB GOLD tests have been shown to be more specific and 310 
sensitive in populations with a low incidence of tuberculosis, but in a country like South 311 
Africa with a higher TB burden the IGRAs have not been shown to be superior to the 312 
tuberculin skin test.74-76 It is also important to note that negative IGRA’s do not exclude 313 
ocular TB as they may be negative in patients with very low CD4 counts.77 314 
Although IGRA’s can distinguish exposure to M. tuberculosis from the Bacillus Calmette-315 
Guérin vaccine strain, they currently lack the specificity to distinguish between latent 316 
tuberculosis infection and active tuberculosis.78 Similarly, testing for serum antibodies to 317 













A very low sensitivity of acid-fast bacilli smear and culture in ocular fluid specimens, and 319 
a long time period (6–8 weeks) for this bacteria to grow in culture are major limitations in 320 
ocular fluid analysis in cases of suspected ocular TB.79  321 
PCR diagnosis of ocular TB has emerged as a potential powerful tool for rapid detection. 322 
It has been shown to be highly specific with a variable sensitivity.79 The reliability of PCR 323 
testing for TB depends on the sensitivity and specificity of a particular assay being used. 324 
These measures are difficult to establish in tuberculosis as the culture that is the gold 325 
standard for comparison itself has a poor yield from intraocular specimens, and 326 
histopathology is mostly not available.  Use of nPCR for MTB may substantially improve 327 
sensitivity.80 In addition, real time PCR for M. tuberculosis has also helped in the 328 
differentiation of Mycobacterium from other contaminants.80 At present there is however 329 
no proven effective and highly sensitive PCR technique for identifying ocular MTB 330 
infection. Better PCR tests for MTB are needed. A recent proposal from Gupta suggests 331 
that nested PCR may increase the sensitivity but this is not proven in any study with 332 
significant numbers.80 333 
 334 
The diagnosis of presumed ocular tuberculosis remains a clinical challenge with currently 335 
available diagnostic modalities. Continued improvement in the currently available 336 
molecular diagnostic techniques including quantitative PCR may be valuable in our ability 337 
to establish an earlier etiologic diagnosis and institute appropriate antimycobacterial 338 
therapy.78 339 
 340 
Ocular Syphilis 341 
Patients with ocular syphilis may present with episcleritis, scleritis, dacryoadenitis, 342 
anterior uveitis, intermediate uveitis, papillitis, retinal vasculitis, neuroretinitis and 343 
chorioretinitis. In the past, ocular syphilis has been described as manifesting most 344 













segment inflammation have been described.81-84 Syphilis is a ‘great imitator’ and so can 346 
present with many phenotypic disease expressions.  Retinitis was recently reported as a 347 
common presentation in HIV-infected individuals, suggesting that HIV infection may 348 
somehow modulate the disease.83 349 
Peripheral blood tests for detecting syphilitic infection include the treponemal and the 350 
non-treponemal tests. The treponemal tests are the fluorescent treponemal antibody-351 
absorption (FTA-ABS) test and the two indirect agglutination treponemal tests, the 352 
Treponema Pallidum Haem Agglutination (TPHA) and the Treponema Pallidum Particle 353 
Agglutination (TPPA) tests. FTA-ABS has a sensitivity of 84% for detecting primary 354 
syphilis infection and almost 100% sensitivity for detecting syphilis infection in other 355 
stages. Its specificity is 96%.85 For primary syphilis, TPPA has a sensitivity of 85% to 356 
100%, and a specificity of 98% to 100%. In secondary and late-latent syphilis, TPPA has 357 
a sensitivity of 98% to 100%. The treponemal tests are however incapable of 358 
distinguishing past from present infection.86-87 359 
In order to determine disease activity including antibody quantitation the non-treponemal 360 
Venereal Disease Research Laboratory (VDRL) test can be used.88 361 
The VDRL test is commonly used to assess response to therapy and to detect CNS 362 
involvement. The basis of the test is that an antibody produced by a patient with syphilis 363 
reacts with an extract of ox heart (diphosphatidyl glycerol). It therefore detects anti-364 
cardiolipin antibodies (IgG, IgM or IgA), visualized through foaming of the test tube fluid, 365 
or "flocculation". The Rapid Plasma Reagin (RPR) test uses the same antigen as the 366 
VDRL, but in that test it has been bound to several other molecules including a carbon 367 
particle to allow visualization of the flocculation reaction without the need of a 368 
microscope. 369 
Many other medical conditions can produce false positive VDRL / RPR results, including 370 













a treponemal test (TPHA or TPPA) in order to confirm the diagnosis, when non-372 
treponemal tests are being used as screening tests. 373 
The non-treponemal tests are very useful as the trend of titres is correlated to disease 374 
activity (i.e. falling titres indicate successful treatment).  375 
If any of these tests (TPPA, TPHA or VDRL) are positive in the CSF, this indicates 376 
neurosyphilis.89 In cases of suspected ocular syphilis, Treponemal tests are the most 377 
appropriate. The non-treponemal tests, VDRL or RPR, are insufficiently sensitive in late-378 
stage syphilis, when ocular disease most often occurs. While the sensitivity and 379 
specificity of treponemal tests are higher, false negative and false positive results are 380 
also observed. The serologic diagnosis of syphilis is far from perfect.90 381 
Ocular fluid antigen and antibody tests have not been proven to be useful.91-93 PCR on 382 
ocular fluids has been used to detect syphilitic uveitis, but no large studies have been 383 
done. 94-95  384 
 385 
INTRAOCULAR FLUID SAMPLING SITES AND TECHNIQUE AFFECTING ACCURACY	  386 
Obtaining ocular fluid for diagnostic testing involves either an aqueous tap or a vitreous 387 
tap.28,96 An aqueous tap can be performed in an outpatient setting, providing 388 
approximately 0.1 to 0.2 mL of fluid.21 Anterior chamber paracentesis is generally safe 389 
(complication rate 0.7%) when performed at the slit lamp following adequate aseptic 390 
precaution, and appropriate counselling.97 391 
A vitreous tap can be performed in the outpatient setting, or in theatre with the aid of an 392 
operating microscope. Vitreous fluid obtained during vitrectomy surgery can also be used 393 
for analysis. This fluid may however be diluted with balanced salt solution entering the 394 
vitreous cavity through the irrigating port. Obtaining a preinfusion aspirate can avoid this 395 
dilution effect. In younger patients where vitreous syneresis has not taken place, a larger 396 
bore needle is often required in order to obtain a sample; alternatively a diagnostic 397 













Both aqueous and vitreous biopsies for PCR diagnosis have been shown to be useful. 399 
20,60 Harper and colleagues found aqueous samples to have a higher sensitivity, but the 400 
difference wasn’t statistically significant and their study was subject to selection bias. 401 
There is inadequate evidence in the literature to evaluate the relative sensitivity of 402 
aqueous versus vitreous fluid samples in PCR analysis in infectious posterior uveitis. A 403 
randomized trial to compare aqueous and vitreous samples sensitivity is required. 404 
 405 
Local information and trends 406 
 407 
Groote Schuur Hospital is located in Cape Town, which is the capital city of the Western 408 
Cape province in South Africa. Groote Schuur Hospital is a large tertiary care hospital 409 
that serves a significant proportion of the approximat ly 3 million population of the 410 
greater Cape Town Metropolitan area. 411 
At Groote Schuur Hospital an average of about 50 patients per year present with 412 
suspected infectious posterior uveitis. There is also a significant HIV burden with an 413 
estimated HIV infection rate of 18% in the Cape Town Metropolitan area in 2008, which 414 
increased to 20% in 2010.98 415 
In this study we set out to determine the pathogen distribution in infectious posterior 416 
uveitis in a representative population with a high HIV infection rate, as well as the value 417 
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Diagnostic and clinical value of routine polymerase chain reaction analysis of 3 
intraocular fluid specimens in the diagnosis of suspected infectious posterior 4 
uveitis 5 
 6 
Scheepers MA, Lecuona KA, Rogers G, Bunce C, Corcoran C, Michaelides M  7 
Groote Schuur Hospital Ophthalmology, Cape Town, South Africa 8 
 9 
Objective: To assess the diagnostic and clinical value of routinely performing 10 
polymerase chain reaction (PCR) analysis on intraocular fluid samples in patients with 11 
suspected infectious posterior uveitis in a population with a high prevalence of human 12 
immunodeficiency virus infection. 13 
Design: Retrospective, interventional case series. 14 
Participants: 159 consecutive patients presenting with suspected active infectious 15 
posterior uveitis. 16 
Methods: Patients presenting with a first episode of suspected infectious posterior 17 
uveitis underwent PCR testing of ocular fluid samples in a tertiary care hospital over a 18 
five year period. PCR analysis was performed for cytomegalovirus (CMV), varicella 19 
zoster virus (VZV), herpes simplex virus type 1 and 2 (HSV), toxoplasma gondii (TG) 20 
and mycobacterium tuberculosis (MTB). 21 
Results: The prevalence of the commonest causes of infectious posterior uveitis based 22 










Scheepers et al – The value of PCR in the diagnosis of infectious posterior uveitis 
 2 
identified. PCR analysis confirmed the initial clinical diagnosis in 55 patients (35%) and 24 
altered the initial clinical diagnosis in 36 patients (23%). The clinical diagnosis prior to 25 
PCR testing was non specific (uncertain) in 51 patients (32%), with PCR providing a 26 
definitive final diagnosis in 20 of these patients (39%); necrotizing herpetic retinopathy 27 
and ocular toxoplasmosis were particularly difficult to diagnose correctly without the use 28 
of PCR analysis.  The overall PCR sensitivity was 84%, specificity was 99%, positive 29 
predictive value was 97% and negative predictive value was 95%. 30 
Conclusion: The clinical phenotype alone was unreliable in diagnosing the underlying 31 
infectious cause in a quarter of patients in this study. Since the outcome of incorrectly 32 
treated infective uveitis can be blinding, PCR analysis of ocular fluids is recommended 33 
early in the disease even in resource poor settings. 34 
 35 
Financial Support: None. 36 























In developed countries, uveitis affects approximately 200 per 100,000 in the population, 49 
and uveitis and its complications accounts for up to 35% of severe visual impairment.1 In 50 
less developed countries, uveitis and its complications are even more common, 51 
affecting an estimated 714 per 100,000 and contributing to 25% of blindness.1 Posterior 52 
uveitis is thought to comprise approximately 5% of all uveitis entities, with the 53 
commonest pathogens responsible for infectious posterior uveitis and panuveitis being 54 
Herpes Simplex Virus (HSV) type 1 and 2, Varicella-Zoster Virus (VZV), 55 
Cytomegalovirus (CMV), Toxoplasma Gondii (TG), Treponema Pallidum and 56 
Mycobacterium Tuberculosis (MTB).2 In developed countries, the most common 57 
infectious aetiologies are TG, HSV, and VZV, whereas CMV is a common pathogen in 58 
countries with a high prevalence of human immunodeficiency virus (HIV) / acquired 59 
immune deficiency syndrome (AIDS).3-5 60 
 61 
Blindness and visual impairment caused by infectious uveitis can be prevented by early 62 
identification of the responsible pathogen, and the subsequent prompt administration of 63 
appropriate antimicrobial therapy.1 This is particularly critical in immunocompromised 64 
patients.3,6 The aetiological diagnosis of infectious uveitis is initially made on the basis 65 
of the associated clinical features, but there is often significant overlap between the 66 
phenotypic expressions of these different pathogens, thereby limiting the ability to 67 
accurately identify the causative organism by clinical examination.7 Moreover, 68 
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AIDS has been reported, making it almost impossible to make a correct complete 70 
diagnosis on clinical grounds alone.8 Furthermore, establishing a diagnosis based on 71 
clinical findings is also difficult in cases where media opacity or poor pupil dilation may 72 
mask clinical features. Under these circumstances an incorrect diagnostic decision not 73 
only causes a delay of appropriate treatment and prevention of loss of vision, but also 74 
exposes the patients to side effects of an unnecessary medication.9 75 
 76 
PCR of intra-ocular fluids is a reliable investigation that can identify most of the common 77 
causes of infective posterior uveitis.10 It is a technique whereby theoretically a single, or 78 
a few copies of a piece of DNA, are amplified across several orders of magnitude, 79 
generating millions of copies of a particular nucleic acid sequence. PCR analysis of 80 
ocular fluid samples allows accurate and rapid detection of small quantities of DNA or 81 
RNA from potential pathogens infecting the eye. It has been shown to be highly 82 
sensitive and specific for CMV, HSV and VZV. 2,6,9,11-17 By comparison, PCR analysis in 83 
cases of TG posterior uveitis ha  a variable sensitivity and a combination of PCR & 84 
Goldman Witmer coefficient analysis improves diagnostic sensitivity. 3,6,18-25 PCR 85 
diagnosis of ocular MTB has been shown to be highly specific with a variable 86 
sensitivity.26 PCR also offers significantly improved time to diagnosis compared to 87 
traditional techniques.  88 
 89 
PCR testing is however not readily available in low income countries and clinicians have 90 
to rely on clinical findings to decide on initial treatment. The prevalence of PCR proven 91 
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yet been described. This study was therefore performed to determine the prevalence of 93 
the commonest causes of infectious uveitis based on PCR studies in a population with a 94 
high prevalence of HIV, and to document the correlation between the clinical 95 
appearance and the laboratory findings in a general ophthalmology clinic to aid the 96 
development of suitable treatment protocols.    97 
 98 
METHODS 99 
Patients and Clinical Methods 100 
Patients who underwent PCR testing of ocular fluids (vitreous and aqueous) for 101 
suspected infectious uveitis at the Ophthalmology Unit at Groote Schuur Hospital 102 
between 1 May 2004 and 30 June 2009 were identified.  The Ophthalmology Unit at 103 
Groote Schuur Hospital in Cape Town, South Africa, is one of 2 tertiary institutions that 104 
serve a population of approximately 3 million. The estimated HIV prevalence in this area 105 
was 18% in 2009.27 Ethics approval for this study was obtained from the University of 106 
Cape Town Health Sciences Human Research Ethics Committee. 107 
 108 
Patients presenting to the Ophthalmology Triage Division with suspected infectious 109 
uveitis underwent routine PCR testing of ocular fluids. Other investigations included 110 
syphilis serology, a full blood count and differential, chest X-ray, and HIV testing if 111 
status was unknown. Skin tests for tuberculosis were not performed as this is of limited 112 
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Based on the phenotypic appearance, the appropriate treatment was commenced 115 
pending the results of the PCR testing. When indicated by the subsequent PCR result, 116 
treatment was changed. The initial diagnosis and management was made by 117 
ophthalmology residents in the Triage Division, after which patients were followed up in 118 
the Uveitis Clinic. 119 
 120 
The study population consisted of the laboratory sample logs of all patients who 121 
underwent PCR testing of ocular fluids between 1 May 2004 and 30 June 2009. Patient 122 
charts were reviewed to determine clinical history and course, as well as patient 123 
characteristics. Patients who had a known previous episode of posterior uveitis were 124 
excluded from the study. PCR testing was performed for the commonest causative 125 
organisms namely CMV, HSV type 1 and 2, VZV, TG and MTB.  126 
 127 
Ocular fluid samples were obtained by Ophthalmology residents and consultants. 128 
Vitreous samples were obtained by passing a 23 gauge needle through the pars plana 129 
and withdrawing 0.2 to 0.3 mls of core vitreous cavity fluid. A small number of vitreous 130 
samples were also obtained at the time of pars plana vitrectomy. If vitreous could not be 131 
aspirated, anterior chamber aqueous samples were obtained using a 28 to 30 gauge 132 
needle on a 1 ml syringe using tetracaine topical anaesthesia and one drop of topical 133 
5% Povidone Iodine solution. Samples were then transported urgently to the diagnostic 134 
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LABORATORY METHODS for PCR analysis 138 
a. Nucleic Acid Isolation 139 
Total nucleic acid was extracted from the aqueous and vitreous fluid using the 140 
Nuclisens EasyMAG platform (bioMérieux, Boxtel, Netherlands) according to the 141 
manufacturer’s instructions. Nucleic acid was eluted in 50µl elution buffer and stored at -142 
4°C.  143 
b. Nested PCR for the detection of CMV, HSV 1 & 2, VZV, TG and MTB. 144 
In-house nested PCRs were used to screen the samples in this study for CMV, HSV 1 & 145 
2, VZV, TG and MTB using previously published primer sequences.28-32 The first round 146 
PCR was performed with a 50µl reaction mixture containing 10µl extracted DNA, 15mM 147 
Tris-HCL (pH 8), 50mM KCl, 1.5mM MgCl2, 0.2mM deoxynucleotide triphosphates 148 
(ABgene, Epsom, UK), 20pmol of each forward and reverse primer and 1.5U 149 
Supertherm Taq polymerase (JMR Holdings, Kent, UK). Amplification was performed on 150 
a Thermo Hybaid PxE 0.2 thermal cycler (Thermo Scientific, Waltham, MA, USA), with 151 
the following conditions: 1 cycle of 94°C for 2 minutes, 40 cycles of 94 °C for 20s, 55°C 152 
for 30s, and 72°C for 45s, and a final elongation step at 72°C for 7 minutes. The second 153 
round PCR was performed using the same basic master mix ingredients containing 154 
50pmol of each inner forward and reverse primer and 2µl of first round PCR product. 155 
Cycling conditions were as for the first round PCR, although the annealing temperature 156 
was increased to 58°C. Amplified products were separated by electrophoresis in 2% 157 
agarose gel, and visualized under UV irradiation after staining with ethidium bromide. 158 
The expected sizes of the inner PCR products were 160bp (CMV), 179bp (HSV 1 & 2), 159 
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accredited molecular laboratory which employs strict precautions to prevent 161 
contamination. 162 
PCR results were reported as detected or not detected within 48 to 72 hours. 163 
 164 
OUTCOME MEASURES 165 
Initial pre-PCR diagnoses were made based on history and clinical findings on ocular 166 
and systemic examination. Final diagnoses were made based on investigation results, 167 
clinical behaviour and response to treatment. PCR test results were considered to 168 
confirm the initial diagnosis if PCR analysis was positive for the pathogen which was 169 
considered the inciting cause at presentation. PCR test results were considered to have 170 
changed the initial diagnosis if PCR analysis was positive for a different pathogen and 171 
the clinical course and response to treatment was consistent with the PCR positive 172 
result. If the PCR test results were positive for more than one pathogen and the clinical 173 
course and treatment response was consistent with possible co-infection then the PCR 174 
test result was also considered to alter the diagnosis. In all other cases the PCR test 175 
result was considered to have an undetermined effect on the final diagnosis.  176 
 177 
There is no gold standard test against which to measure the sensitivity and specificity of 178 
PCR analysis in the diagnosis of infectious posterior uveitis.33 The final diagnoses which 179 
were based on the clinical course, response to treatment and results of investigations 180 
were therefore used as the gold standard in order to calculate PCR sensitivity and 181 
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sensitivity of the test itself.33 Positive predictive value (PPV) and negative predictive 183 
value (NPV) for PCR testing were also calculated. 184 
 185 
Statistical analysis was performed by Dr. C Bunce from the Moorfields Eye Hospital 186 
Medical Statistics department. A Chi-square test was used to compare sensitivity values 187 




Of the 187 consecutive patients who underwent PCR ocular fluid testing, 159 patients 192 
were included in the study.  There were 28 patients excluded from the study; 11 case 193 
notes were damaged or lost, 4 patients had a recurrent episode, 12 patients did not 194 
have any active posterior uveitis at the time of sampling, and 1 patient defaulted follow 195 
up within 1 week of presentation, preventing observation of clinical course and 196 
confirmation of the final diagnosis.  197 
There were no documented complications due to aqueous or vitreous fluid aspiration 198 
procedures. 199 
 200 
Patient characteristics and average visual acuities pre- and post treatment are shown in 201 
tables 1 and 2 respectively. The duration of follow up ranged from 1 week to 5 years. 202 
The number of PCR tests performed for each pathogen tested and the results are 203 
shown in table 3. There were 643 PCR tests performed, with a mean of 4 tests per 204 
patient. CMV, VZV, HSV and TG PCR tests were performed on most patients, whereas 205 
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available for the last 18 months of the study (from January 2008). Forty one patients 207 
were tested for all 5 pathogens.  208 
 209 
Initial Clinical Diagnoses 210 
The pre-PCR clinical diagnoses compared with PCR positive findings are shown in table 211 
4. The most common pre-PCR diagnoses were cytomegalovirus retinitis (CMVR) 212 
(n=70), necrotizing herpetic retinopathy (NHR) (n=14), and ocular toxoplasmosis (OT) 213 
(n=10). There were 51 patients whose diagnoses were uncertain because their clinical 214 
presentations were not characteristic for a particular pathogen. In 17 patients the view 215 
of the fundus was so poor due to a combination of severe vitritis and posterior 216 
synechiae, that it precluded accurate clinical diagnosis. 217 
 218 
PCR Results 219 
Of the 159 patients tested by PCR analysis, 94 patients had a positive PCR result 220 
(59%). PCR confirmed the suspected diagnosis in 55 patients (34.6%), altered the 221 
diagnosis in 36 patients (22.6%) and had an undetermined effect in 68 patients (42.8%). 222 
In the 51 patients who had an uncertain clinical diagnosis, PCR identified 20 patients 223 
(39%) with a PCR positive diagnosis consistent with the final diagnosis. CMV PCR tests 224 
were the most frequently positive (47%), followed by VZV (11%). There were no positive 225 
HSV PCR results. 226 
 227 
Five patients tested PCR positive for more than one pathogen. Four patients were CMV 228 
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CMV and VZV positive, two were considered to have true active co-infections with CMV 230 
and VZV, one had a final diagnosis of CMVR alone and one had a final diagnosis of 231 
NHR due to VZV alone. The patient who tested positive for both CMV & TG had a final 232 
diagnosis of OT alone. Three of the five co-infections were therefore considered to be 233 
‘false positive’ results. 234 
 235 
Final diagnoses are shown in table 5. CMV retinitis was bilateral in 36 cases (49%), 236 
NHR was bilateral in 6 cases (35%), and OT was bilateral in 2 cases (13%).  Using the 237 
final diagnoses as the gold standard, PCR sensitivities for the sampling sites, specificity, 238 
positive predictive value and negative predictive values were calculated and the results 239 
are shown in tables 6 and 7. The overall PCR sensitivity for pathogens tested was 84%. 240 
 241 
Despite 148 samples being tested for HSV by PCR analysis, none were HSV positive. 242 
Simultaneous vitreous and aqueous specimens were obtained from 4 patients, solitary 243 
vitreous samples were taken from 105 patients, and solitary anterior chamber fluid 244 
samples from 47 patients. Sampling site information was omitted in 3 case notes (all 3 245 
solitary samples). There were 2 patients who had repeat sampling during their treatment 246 
course (both vitreous repeat samples). Overall, vitreous samples had higher sensitivity 247 
than aqueous (P = 0.027).  248 
Seventeen patients presented with a very poor view of the fundus. Seven cases were 249 
due to OT (4 of these were PCR confirmed) and 2 cases were due to CMVR (both PCR 250 















Bilateral v Unilateral Disease 255 
Of the 67 patients who presented with bilateral disease, 36 (54%) were due to CMV, 6 256 
(9%) were due to NHR and 2 (3%) were due to OT.  Of the 92 patients who presented 257 
with unilateral disease, 38 (41%) were due to CMV, 11 (12%) were due to NHR and 14 258 




This is the first study to describe the pathogen distribution based on PCR testing of 263 
patients with infectious posterior uveitis, in a population with a high prevalence of HIV / 264 
AIDS. The most frequent final diagnosis was CMVR, followed by NHR and OT (47%, 265 
11% and 10% respectively). This is in direct contrast to Harper et al’s study in a 266 
population with a lower HIV prevalence where NHR was the most common diagnosis 267 
followed by CMVR and OT.33 268 
 269 
The initial pre-PCR clinical diagnosis was uncertain in 51 cases (32%). This was due to 270 
a number of factors. Many patients presented late with significant vitritis and posterior 271 
synechiae leading to an obscured fundus view. A significant number of cases presented 272 
with atypical findings making it difficult to make a definitive diagnosis. In addition, the 273 
initial clinical diagnosis was usually made by general ophthalmologists, not uveitis 274 
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relevant, especially in the developing world, but also potentially in developed countries. 276 
PCR analysis provided the correct final diagnosis in 20 of these patients (39%). 277 
 278 
The initial clinical diagnosis changed in approximately a quarter of cases as a result of 279 
PCR testing. This is likely due to the significant overlap between the phenotypic 280 
expressions of these different pathogens.7 Having an early definitive laboratory proven 281 
diagnosis is advantageous in instituting appropriate effective treatment in a timely 282 
fashion; this was not the case in a quarter of our patient population. In our study the 283 
clinical diagnosis prior to PCR testing was particularly challenging in patients who were 284 
subsequently confirmed to have NHR and OT, often due to a poor view of the fundus. 285 
Patients with NHR from VZV infection had findings that overlapped with CMV retinitis; 286 
whilst patients with OT were found to overlap with CMV retinitis and NHR phenotypes. 287 
 288 
PCR was able to provide a final definitive clinical diagnosis in approximately 60% of our 289 
patients. Previous studies have shown PCR analysis of intraocular fluids to detect viral 290 
infection in posterior uveitis to be a sensitive and highly specific test. For CMV retinitis 291 
sensitivity ranges from 91% to 95% and for NHR sensitivity ranges from 79% to 292 
100%.6,9,11-13,16-17 Our study supports these findings with a viral sensitivity of 91% for 293 
CMV and 75% for NHR.  294 
PCR analysis in patients with ocular toxoplasmosis is generally less sensitive than viral 295 
retinitis. Studies have shown variable sensitivity ranging from 27% to 85%.6,18,21-25 It has 296 
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sensitivity.6 This is supported in our study where we found the sensitivity to be 75%. 298 
The diagnostic yield for PCR for toxoplasmosis chorioretinitis in this series was 299 
comparable with that for viral retinitis (12 of 16 cases, or 75%) and is higher than the 9 300 
of 25 cases (36%) reported by De Groot-Mijnes et al, or by Fardeau et al for 34 patients 301 
with a final diagnosis of toxoplasmosis chorioretinitis, of whom 79% had positive 302 
intraocular antibodies and only 27% demonstrated positive PCR results.6,18 Fardeau et 303 
al concluded that large lesions in immunocompromised individuals were more likely to 304 
have positive results. In the series reported by Groot-Mijnes et al, results for intraocular 305 
antibody production were positive in 92% of patients, and, in contrast to viral retinitis, 306 
delayed testing by more than three weeks after onset of symptoms was more likely to 307 
lead to positive PCR results for toxoplasmosis. In our study improved sensitivity would 308 
most likely have been achieved with the addition of Goldman Witmer Coefficient 309 
antibody testing. 310 
 311 
The PCR sensitivity for MTB in our study was low. Better PCR tests for MTB are 312 
needed. A recent proposal from Gupta suggests that nested PCR may increase the 313 
sensitivity but this is not proven in any study with significant numbers.34 314 
 315 
The overall sensitivity of PCR testing in our study was 84% and the specificity was very 316 
high at 99%, which are comparable to Harper’s study (sensitivity of 81%; specificity of 317 
97%.)33 The timing of PCR testing may have played a role in the high sensitivity 318 
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sensitivity is thought to be maximal), as opposed to being used later in the disease if 320 
there is no response to initial treatment.  321 
 322 
There were 3 false positive results in our study. Both CMV and VZV were isolated in 2 323 
of these cases, but clinical presentation and course suggested CMV infection only. Both 324 
CMV and TG were isolated in the third case, CMV was considered falsely positive as 325 
the clinical presentation and course suggested TG infection only. These false positives 326 
may have been due to previous resolved infection with a small number of ‘old’ viruses 327 
still being present in the eye, or it may be due to virus in the systemic circulation leaking 328 
into the eye across a compromised blood ocular barrier, but not causing active infection 329 
in the eye.  The false negative rate in our study was relatively low. This is in part 330 
attributable to the fast transport time to the on site laboratory, and may also be due to 331 
the high number of immunocompromised patients in our study.  332 
 333 
The positive predictive value, defined as the likelihood of having disease related to the 334 
tested infectious agent given positive PCR results, was very high at 97%. The negative 335 
predictive value (NPV), defined as the likelihood of not having the specified disease 336 
given negative PCR results, was also very high at 95%. This is a high negative 337 
predictive value compared to Harper who found their NPV to be 68%.33 The negative 338 
predictive value is a function of both the sensitivity of the test and the prevalence of the 339 
disease being tested for. Since PCR testing is particularly sensitive and almost 60% of 340 
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expected. This was of particular value in the 51 cases (32%) with uncertain diagnosis, 342 
where infectious uveitis could be excluded with confidence following a negative result.  343 
 344 
In our study vitreous samples were more likely to provide a positive diagnosis (P = 345 
0.027). There may however be selection bias and as a result it is difficult to draw any 346 
definite conclusion from this finding. Harper’s study showed better sensitivity for 347 
aqueous compared to vitreous samples but their findings were not statistically 348 
significant.33 No randomized trials exist at present to prove which is better.  349 
 350 
No HSV was detected in any of our patients. Laboratory error was thought to be unlikely 351 
as external investigators confirmed the validity of the local laboratory HSV PCR 352 
detection method. Also, the local laboratory cerebrospinal fluid HSV PCR detection rate 353 
in patients with suspected HSV encephalitis is similar to published studies from around 354 
the world. This points to the possibility of a different epidemiology of necrotizing herpetic 355 
retinitis in our local population.  356 
 357 
A large proportion of eyes presented with very poor vision. Although there was no 358 
improvement in the mean visual acuities of affected eyes, we believe that by instituting 359 
the appropriate treatment we may have prevented more eyes from going blind.  360 
 361 
There are a number of inherent limitations to our study. It was retrospective and criteria 362 
for performing PCR were not specified – although all patients with presumed infectious 363 
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there was a relatively high drop out rate to follow-up. Also, this was not a population 365 
based study but a referral centre study resulting in possible selection bias. 366 
 367 
In summary, the prevalence of the commonest causes of infectious posterior uveitis 368 
based on PCR studies in a population with a high prevalence of HIV was CMV in 47%, 369 
VZV in 11% and OT in 10%. Tuberculosis was rare and HSV was not identified. On the 370 
basis of these findings, in the absence of the availability of PCR testing, the treatment of 371 
infectious posterior uveitis with intra-vitreal ganciclovir and systemic acyclovir, would be 372 
appropriate in 58% of cases.  PCR testing changed the diagnosis in a quarter of cases, 373 
and confirmed the presence of infective uveitis in another third of cases. Since the 374 
outcome of incorrectly treated infective uveitis can result in irreversible blindness, PCR 375 
analysis of ocular fluids is recommended early in the disease process even in resource 376 
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TABLE 1. Patient characteristics 
 
Mean age 34 (Range 14 - 53) 
Gender  
   Male 58 
   Female 101 
Laterality  
   Bilateral 67 
   Right eye 42 
   Left eye 50 
HIV +ve 142 
HAART treatment @ presentation 65 
MTB treatment @ presentation 67 
 
HIV = human immunodeficiency virus 




TABLE 2. Average visual acuities (VA) pre- and post treatment 
 
 Pre treatment Post treatment 
VA ≥ 6/18 42% 33% 
VA 6/24 - 4/60 16% 14% 
VA ≤ 3/60  42% 53% 
Eyes assessed 226 191 
 




TABLE 3. PCR tests performed 
 
Infectious agent No. tests perf. No. +ve % +ve 
CMV 154 72 47% 
TG 150 12 8% 
VZV 148 17 11% 
HSV 148 0 0% 
MTB 43 1 2% 
TOTAL TESTS 643 102 16% 
 
 














CMV   
& VZV 
+ve  
CMV   
& TG  
+ve 
PCR +ve rate 
No.      % 
           
CMV 70 51 4  4  1  60 86% 
NHR 14 3 2  3  2  10 71% 
TG 10 1   1    2 20% 
MTB 7     1   1 14% 
Syphilis 5        0 0% 
IRU 2        0 0% 
Unsure 51 11 5  3  1 1 21 41% 
TOTAL 159 66 11 0 11 1 4 1 94 59% 
 






















CMV/VZV coinfection 2 
HIV associated retinopathy 2 
Toxocara Canis 1 
Immune reconstitution uveitis 1 
Blood dyscrasia 2 




TABLE 6. Sensitivity, specificity, positive predictive value & negative predictive value for each pathogen 




True +ve False +ve True -ve False -ve Sens Spec PPV NPV 
CMV 154 69 45% 1 1% 74 48% 7 5% 91% 99% 99% 91% 
   AC  45 13 29% 0 0% 31 69% 1 2% 93% 100% 100% 97% 
   V    106 56 53% 1 1% 43 41% 6 6% 90% 98% 98% 88% 
   NS   3 2 67% 0 0% 1 33% 0 0% - - - - 
VZV 148 15 10% 2 1% 126 85% 5 3% 75% 98% 88% 96% 
   AC  43 1 2% 0 0% 39 91% 3 7% 25% 100% 100% 93% 
   V 102 14 14% 2 2% 84 82% 2 2% 88% 98% 88% 98% 
   NS  3 0 0% 0 0% 3 100% 0 0% - - - - 
TOXO 150 12 8% 0 0% 134 89% 4 3% 75% 100% 100% 97% 
   AC 45 1 2% 0 0% 43 96% 1 2% 50% 100% 100% 98% 
   V 102 11 11% 0 0% 88 86% 3 3% 79% 100% 100% 97% 
   NS  3 0 0% 0 0% 3 100% 0 0% - - - - 
MTB 43 1 2% 0 0% 39 91% 3 7% 25% 100% 100% 93% 
   AC 20 1 5% 0 0% 16 80% 3 15% 25% 100% 100% 84% 
   V 22 0 0% 0 0% 22 100% 0 0% 0% - - 100% 
   NS  1 0 0% 0 0% 1 100% 0 0% - - - - 
TOTAL 495 97 20% 3 1% 373 75% 19 4% 84% 99% 97% 95% 
 
AC = Anterior chamber     V = Vitreous      NS = Not specified        Sens = sensitivity     Spec = Specificity 
PPV = positive predictive value   NPV = negative predictive value 
 
1.Three patients had samples taken from an unknown site (not specified in the clinical notes) 
2. Simultaneous vitreous and aqueous sampling was performed on 4 patients 









True +ve False +ve True -ve False -ve Sens Spec PPV NPV 
AC  153 16 10% 0 0% 129 84% 8 5% 67% 100% 100% 94% 
V  332 81 24% 3 1% 237 71% 11 3% 88% 99% 96% 96% 
NS  10 2 20% 0 0% 8 80% 0 0% - - - - 
TOTAL 495 97 20% 3 1% 373 75% 19 4% 84% 99% 97% 95% 
 
AC = Anterior chamber     V = Vitreous      NS = Not specified        Sens = sensitivity     Spec = Specificity 
PPV = positive predictive value   NPV = negative predictive value 
 
1.Three patients had samples taken from an unknown site (not specified in the clinical notes) 
2. Simultaneous vitreous and aqueous sampling was performed on 4 patients 



















A.  INTRODUCTION – Basic Information 
 








CASE REPORTS  
CLINICAL TRIAL REGISTRATION 
CONFLICT OF INTEREST (financial disclosure) 
COPYRIGHT ASSIGNMENT FORM 
CORRESPONDING AUTHOR DECLARATION  
COVER FIGURES 
DRUG and EQUIPMENT 
MANUFACTURER NAMES 
EDITORIALS 
ENGLISH EDITING ASSISTANCE 
EVIDENCE BASED STUDIES  (additional 
guidelines)  
FIGURES 
FINANCIAL SUPPORT (funding) 
IN PRESS/ONLINE RELEASE  
INSTITUTIONAL REVIEW BOARD 
LEGENDS 
LETTER TO THE EDITOR/REPLY 
LITERATURE REVIEW  
MANUSCRIPT TEXT FORMAT 
ONLINE ONLY PUBLICATIONS   
ONLINE SUPPLEMENTAL MATERIALS 
PERMISSION TO USE COPYRIGHTED MATERIALS 
PRÉCIS   
PRIOR AND REPETITIVE PUBLICATION 
PRECEDENCE 
REFERENCE FORMAT (with examples) 
REJECTION OF MANUSCRIPTS 
REPRINTS  
REVIEW AND PUBLICATION PROCESS 
REVISION SUBMISSION  
STATISTICS  
STUDY DESIGN  
TABLES 
TRANSLATIONAL SCIENCE REVIEW 
TYPES OF SUBMISSIONS 
USER NAME AND PASSWORDS  
VIDEO CLIPS 
  
C.  DOWNLOADABLE FORMS 
 
D.  MISCELLANEOUS INFORMATION  
       1.  DEVELOPING A MANUSCRIPT  
       2.  EQUIVALENT VISUAL ACUITY MEASUREMENTS 
       3.  GLOSSARY OF TERMS  
       4.  GRAMMAR/LANGUAGE GUIDE 
 
Please note:  For convenience browsing of the text, please use bookmarks at the 












A. INTRODUCTION – Basic Information 
 
To submit a manuscript go to http://ees.elsevier.com/ophtha and 
log in as an author.  This site is also available through the 
http://www.ophsource.org/periodicals/ophtha or AAO 
(www.aao.org) websites. 
 
If you have submitted to or reviewed for Ophthalmology since August 2004, a username and 
password have been provided to you.  The username and password are the same regardless of 
whether you are signing in as an author or a reviewer.  If you believe you are in the system 
already or if you cannot remember your username and password please refer to the Username 
and Passwords section in this guide for various ways to verify whether or not your 
information is already in the system.    
 
If you are unable to access the system, please contact the Editorial Office by email at 
aaojournal@jhmi.edu or by phone at 443-848-8496.  Please do not register a second time 
if you believe your information should already be in the system. 
 
AS OF JANUARY 2012, ALL COPYRIGHTS AND CONFLICT OF INTEREST 
FORMS SHOULD BE UPLOADED INTO THE SYSTEM AT TIME OF ORIGINAL 
SUBMISSIONAND WILL BE MANDATORY BY FIRST REVISION SUBMISSION.  
IF THESE FORMS ARE NOT IN A FIRST REVISION SUBMISSION THE 
MANUSCRIPT WILL BE RETURNED TO AUTHORS TO ENABLE THEM TO 
UPLOAD THE FORMS AS NEEDED.   
 
It is the corresponding author’s responsibility to keep all contact information (address, 
institution, phone number and email address) current.  All manuscript communications are 
done by email, only to the corresponding author.   
 
Prior to actually submitting on line, have the following files on your computer ready for 
uploading: copyright form(s), conflict of interest form(s), manuscript (including title page, 
abstract and references), and précis.  As appropriate for your submission, tables should be in a 
separate file and not in the text; a separate file for each figure submitted and another separate 
file containing all the figure legends.   If submitting a revision you will also need to have a 
point by point response file containing a word file with your answers or noted changes to the 
issues raised by the editor, reviewers and/or the editorial office. If possible we request that 
you upload two separate files of the manuscript – one showing all track changes and the other 
a clean version.  PLEASE NOTE:  In order to keep PDFs that go to reviewers and editors at a 
reasonable size, copyright(s) and ICMJE conflicts of interest forms will show only as a link in 
the PDF that you approve.    
Once you upload the files, the system will automatically put them in the correct order.  The 
system will then prompt you to go to “Submission Waiting for Author’s Approval” on your 
author main menu.  If necessary, you can exit the system at this time and come back and 
approve at a later time.  You will find it in your author queue either under pending approval or 
incomplete items depending on how long it has sat in the system awaiting approval.  You will 
need to view your submission and either approve or make corrections and repeat the process 
until you can approve it.  Incorrect file formats or missing required pieces of the submission 
will prevent your PDF from building or your being able to approve it.  If you note an error in 











make changes to the files on your hard drive and upload them again and remove the incorrect 
file.  Changes can not be made to files that are uploaded.  At the last step when you are ready 
to approve your submission and “Submit to Journal Office” you must also read and agree to 
the Ethics in Publishing Statement.  A link is provided to the statement and you agree to it by 
checking off the box on the far right of the submission approval page. 
 
Once you “Submit to Journal Office” you will get an acknowledgement from the Editorial 
Office.  Then a second email will advise you of the manuscript number which should be 
referred to in all communications regarding your submission. 
Please note that you can stop and return to entering a submission at another time. After 
logging in again, you will find the work done previously under “incomplete submissions” on 
your main author menu. 
 
B. DETAILED SPECIFICS 
 
ABBREVIATIONS/ACRONYMS 
Please be sure all abbreviations/acronyms are spelled out at first use in the abstract and again 
at first use in text.  An abbreviation/acronym should appear first in parentheses immediately 
after the term or phrase to which it refers. Every abbreviation used in any table or figure 
should be defined in each corresponding legend.     
 
The following abbreviations have been deemed as accepted and understood abbreviations 
without any further clarification needed.  With these acronyms, no definitions are required at 
any point in the text (not even first use) and they are also acceptable in titles: 
 
AIDS  acquired immune deficiency syndrome 
cDNA  copy deoxyribonucleic acid 
CNS  central nervous system 
DNA  deoxyribonucleic acid 
HLA  human leukocyte antigen 
IM  intramuscular(ly) 
LASIK laser in situ keratomileusis 
mRNA messenger ribonucleic acid 
RNA  ribonucleic acid 
 
ABSTRACT 
 Abstracts are required for Manuscripts, AAO Meeting Papers, Evidence Based Studies and 
Translational Science Reviews.  Abstracts serve many purposes; one is to draw readers to 
your manuscript.  Another is to allow a summary of your manuscript to be reproduced in a 
stand-alone format.  Manuscripts without the required structured abstract will not be reviewed 
until the required abstract is received.  Please spend extra time to develop a simple, clear and 
concise abstract.  All abbreviations in abstracts must be defined at first use except for those 
found in Abbreviations.   
 
Abstracts for Manuscripts and AAO Meeting Papers should not exceed 350 words and 
should be submitted on a separate page in the text.  Deletion of any required section of the 
abstract must be justified in the “Enter Comments” section of the submission process.  The 
following seven sections must appear in your abstract, the author may select the more 
appropriate heading for each section:    
 











2. Design: identifies the study design using a phrase such as cross-sectional study, 
clinical trial, evidence based study, etc.  Study design types are available in the 
Study Design Schemes section of this guide.  Please select a study design from the 
choices listed there.  Worksheet #1 (modified CONSORT agreement) for 
randomized controlled trials has been required since 1996 and is available online.   
3. Participants and/or Controls: states the number of persons or eyes studied and the 
number of controls if a separate control group is included. If a single case is being 
described, the study design section should indicate it as a Case Report, modified 
by “interventional” or “observational”, as appropriate.  The Participant section 
may be deleted for a single case report. 
4.  Intervention or Methods or Testing:  describes the principal treatment(s), 
procedure(s), test(s), or observation(s) performed. 
5.  Main Outcome Measures: defines the main parameter(s) being measured (e.g., IOP, 
vision, ERG, inflammation, etc.) 
6.  Results: briefly summarizes the principal measurements (data) obtained. 
7. Conclusions: states the conclusion(s) derived from the data analysis. 
 
Abstracts for Evidence-based Studies  m ust be lim ited to 250 words and include the 
following five sections: 
              
            1.  Topic: identify the specific clinical problem and therapy to be evaluated.  
2.  Clin ical relevance: characterize the magnitude/importance of the p roblem/disorder 
and define the current standard of care.   
3.  Method s/literature reviewed : d escribe th e sources  of peer-rev iewed m aterials 
utilized and dates of publication. 
4.  Results: summarize the m aterials identi fied and obvious contrasts with prior and 
current standards of care. 
5.  Conclusion: summ arize the strength of  evidence for the recomm ended therapy or 
test. 
 
Abstracts for Translational Science Reviews are unstructured and not to exceed 250 words. 
 
ACADEMY PAPERS AND POSTERS:    
The Academy's journal, Ophthalmology, is eager to receive manuscripts based on Annual 
Meeting presentations.  Although speakers are no longer required to submit a manuscript to 
the Journal; the Academy and the Journal retain an indefinite legal right of first refusal for the 
primary manuscript based on any paper or poster presentation (this does not include items 
presented at subspecialty days).  You are encouraged to submit a manuscript to the Journal 
before, during or after the Annual Meeting. Be sure to note on the cover page of the 
manuscript that it is an Annual Meeting paper or poster.  Since the Journal holds a right of 
first refusal, these manuscripts can only be submitted elsewhere if the Journal declines to 
accept them or a waiver is granted from the Editor-in-Chief. Documentation that the 
manuscript has been declined will be in the form of a "rejection" letter or e-mail from the 
Journal office granting the waiver. For ANY manuscript based on a paper or poster 
presentation from an Academy Meeting, be sure to select “AAO Meeting Paper” for the 
document type; DO NOT USE “Manuscript” in these instances. 
 
ACKNOWLEDGMENTS 
The journal requires acknowledgment to anyone who makes substantial contributions to a 
manuscript but does not qualify as an author.  Please refer to the Authorship section of this 












The Journal will also acknowledge those who reviewed, discussed, edited scientific content, 
referred patients, translated references, provided extensive statistical assistance, or provided 
essential tissue, equipment, or other materials without which the study could not have been 
completed. (See: Lichter PR. The author wishes to thank [editorial]. Ophthalmology 
1988;95:293-4.) In such cases written permission from the person being acknowledged is 
required.  
 
The Journal does not print acknowledgments for those who participated in studies (patients) 
or those who edited for grammar or formatting, or typed a manuscript, or gave “helpful," or 
"moral" support or similar collegial aid to the authors. The Journal does not publish 
acknowledgments of individuals who, by virtue of doing their job, contributed to the 
implementation of the study, e.g., secretaries, clinic coordinators, technicians, ophthalmic 
photographers, or technologists. 
 
AUTHORSHIP  
Authorship Criteria  
The Journal adheres to the Uniform Requirements set by the International Committee of Medical 
Journal Editors (http://www.icmje.org/) for authorship. Each author must meet criteria for 
authorship. To qualify for authorship, authors must make substantial contributions to the 
intellectual content of the paper in each of the three categories: 
Category 1: conception and design, data acquisition or data analysis and interpretation. 
Category 2: drafting the manuscript and or critical revision of the manuscript. 
Category 3: statistical analysis, obtaining funding, administrative, technical or material support, 
or supervision 
. 
The Editor prefers not to police this; we tend to rely on the corresponding author to confirm if 
someone meets criteria.  Please understand though that this editor does not accept “the paper is 
fine with me – no changes” as adequate “critical review of the manuscript and provision of 
intellectual content.”  Our reviewers tend to offer from a few paragraphs to a few pages of input; 
a thoughtful and engaged coauthor might be expected to provide at a minimum a similar amount.  
 
Every author must fill out an Authorship Criteria Statement and forward it to the Corresponding 
Author.   These forms should not be uploaded unless requested by Editors. Upon request, 
these forms can be scanned and emailed to aaojournal@jhmi.edu or uploaded with a revision.  Be 
sure to include the manuscript number in the email.  The Editor may require that the number of 
authors be reduced if authorship criteria are not met.  Of course, each author must still submit the 
copyright and conflict of interest forms.  These should be submitted online with the manuscript. 
 
Guest/Ghost Authors  
Based on the definition of ghost authorship as the failure to designate an individual who has made 
a substantial contribution to the research or writing of a manuscript (see the paper in JAMA. 
2008; 299 (15):1800-12), THE JOURNAL DOES NOT ALLOW GHOST AUTHORSHIP. If 
it comes to light that substantial contribution has not been disclosed, the Editor shall advise the 
corresponding author and withdraw the submission from the system. 
 
Based on the definition of guest authorship as the designation and acknowledgment of an 
individual who has contributed significantly but does not meet authorship criteria, any guest 
authors must a) provide written permission to the corresponding author which is to be 
uploaded with the submission b) be listed by the corresponding author in the 
acknowledgments section (after text and before references in manuscript file) for their 
contribution (e.g., James Smith for statistical analysis.)  If the guest author is being 











a manuscript draft for the named authors to edit or if the named authors prepared the manuscript 
and received writing and formatting assistance from guest author.  If not self employed, the 
guest author should disclose the name of their employer and the funding source.   
 
Corresponding Author 
The Corresponding Author is the person responsible for a submission and all communication with 
the Journal regarding that submission. The Corresponding Author must advise the editors and 
editorial office,  via questions within the submission process, of the following : 
- Receipt of the authorship criteria forms from all authors and confirm that all authors qualify. 
The authorship criteria forms should not be uploaded with the submission but should be 
available if requested 
- - Responsible to disclose and acknowledge any guest author based on the definition of 
“guest authorship” as an individual who does not meet authorship criteria but has made a 
substantial contribution to the research or writing of a manuscript.  
- Responsible to make sure there are no “ghost writers” defined as an individual who has made a 
substantial contribution but  does not qualify as an author and has not been disclosed to the 
Editor.    
- Acknowledge receipt of and upload ICMJE conflict of interest and copyright forms from all 
authors; conflict of interest forms are to be sent and requisite disclosures should be reported on 
the manuscript’s cover page 
- Advise editors whether the submission was funded by the US National Institutes of Health 
(NIH).  Articles accepted for publication in Ophthalmology from authors who have indicated that 
the underlying research reported in their articles was supported by an NIH grant will be sent by 
Elsevier to Pub Med Central for public access 12 months after final publication. The version of 
the article provide by Elsevier is the final accepted version after peer-review but without 
copyediting. 
- Confirmation that Institutional Review Board issues have been addressed in Methods section of 
manuscript 
- Confirmation of awareness that the Journal sometimes, only after acceptance of a submission 
and on a confidential basis and with no rights prior to embargo date, share some information with  
AAO public relations and EyeNet for press release and write up purposes.  
 
Study Group/Writing Committee Authorship 
If study group/writing committee authorship is used and the corresponding author is the Study 
Chair, please state this in the cover letter. However, if he/she is not the chair, please enclose with 
the cover letter a statement from the Study Chair that the group authorship as stated on the cover 
page and/or members of responsible writing committee are both correct.   
The Journal is very aware of the need for transparency of authorship to editors, reviewers and 
readers. Why is transparency needed?  There are many reasons.  Here are examples.  Intellectual 
property (IP) may be debated; authors of manuscripts might cite this as part of claiming IP.  Non-
authors have less of a claim in this regard.  Although we hope not, your paper may contain 
libelous material; someone might sue the authors.  If there is a group, they might sue each group 
member.  I would not be surprised to learn from your attorney that in fact the attorney believes his 
or her client did not really author the work – “so and so, the members of the writing team, really 
wrote it ...”  Our readers want to know who stands behind the claims, who did the work and who 
wrote the paper?  Promotions committees in some instances value first, second, last and group 
authorship differently.  They need and ask for transparency on this issue.   
  
Study groups are important, usually accomplish much more, and often produce more important 
work than independent investigators.  Study groups are to be applauded – the group is stronger 
than the whole; however, understand that this editor does not accept “the paper is fine with me – 











Our reviewers tend to offer from a few paragraphs to a few pages of input; a coauthor might be 
expected to provide, at a minimum, a similar amount.  
 
Members of the group can be listed in initial group papers in print and in subsequent papers, 
either by reference to an earlier manuscript, or at times for length and format reasons, in on line 
supplemental material.  Members are appropriately acknowledged by the byline “…for the XYZ 
Study Group” or “… on behalf of the XYZ Group.”  If you believe group members are more 
appropriately acknowledged by including them as authors, then each and every one must meet 
authorship criteria, we may ask for each authorship criteria form, and each author’s conflicts of 
interest (COI) or financial interests must be disclosed according to our standard COI policies.  We 
may ask for documentation of intellectual input and evidence of satisfaction of the various 
authorship criteria. 
 
Keep in mind that transparency also requires the disclosure (in acknowledgment section) of any 
persons who contributed significantly but did not meet authorship criteria (guest authors).  Also 
remember that NO GHOST AUTHORS ARE PERMITTED. With transparency and space 
limitations in mind, the following are the policies for Ophthalmology regardi g study 
group/writing committee authorship: 
 
1)  If an individual is authoring for a group (e.g., a chairman) it should be listed as  
                           Henry A. Fiddle, MD for the Laser ROP Study Group 
 
2)  Small study groups (< 10 members) can author as the group or they can list writing 
committee  members names “and the XYZ Study Group” as long as all the members 
actually qualify as authors, otherwise only those that do qualify should be listed and the 
remainder can be acknowledged if they had significant, but not qualifying for authorship, 
input.  Anyone listed as an author must complete the authorship criteria form and conflict 
of interest form and submit them to their corresponding author. 
Debra L Hanson, MS; Susan y. Chu, PhD; Karen M. Farizo, MD; John W. Ward, MD; 
and the Adult and Adolescent Spectrum of HIV Disease Project Group 
         
     3)  Large study groups (>10 members) should not author a paper as an entity.  In large 
groups it is not likely that every single member of the group or network contributed as 
required by authorship criteria mentioned above.  Large study groups should either list the 
writing committee members as authors and then “for the XYZ Study Group” or list 
“Writing committee for the XYZ Study Group*” as the author and the names of the 
writing committee members will be listed at the end of the article with the asterisk.  Either 
way, members of the writing committee must qualify as authors and complete the 
authorship criteria forms and conflict of interest forms and submit them to their 
corresponding author.                                   
      Debra L Hanson, MS; Susan y. Chu, PhD; Karen M. Farizo, MD; John W. Ward, 
MD for the Adult and Adolescent Spectrum of HIV Disease Project Group    
                 OR   The Writing Group for the DISC Collaborative Research Group* OR The DISC 
Collaborative Research Group Writing Committee* 
                   
           The first preference is to list the names of the members of the Writing committee and then say for 
the XYZ group. Alternatively, you can just mention the writing group as a whole with asterisk 
which further in the text lists names of the writing committee members.  Full study group 












 ANY digression from these authorship guidelines must be addressed, prior to submission, via 
email to aaojournal@jhmi.edu and the Managing Editor and/or Editor-in-Chief will discuss with 
the Corresponding Author on a case by case basis.  
 
            Entering Authors into the Submission System 
Enter the name, degree(s) and affiliated institution for the first 8 authors. No more than 8 authors 
can be entered in but you should list all authors on the title page of the manuscript.  Please 
provide no more than 2 degrees for each author.  Be sure to indicate which author is the 
corresponding author by checking the appropriate box.  All correspondence regarding a 
submission must come from and will be sent to the corresponding author only. The order of the 
authors can be changed by double clicking on the arrow which points in the direction you want 
that name moved. It will only move one space each time you click on it.  Please do not have staff 
members list themselves as authors for the purpose of uploading files. 
 
NOTE:  
Once a manuscript has been submitted, the order of authorship (including adding or removing 
authors) CAN NOT be changed without a written request to the Editorial Office from the 
corresponding author. This request must include a statement that all authors are in agreement with 
the change along with a new copyright form, both signed by all authors. Specifically, if an author 
is removed, a letter from that author agreeing to his/her removal is required. The new copyright 
form must show the title and authors’ names in the order they should appear in print on the top of 
the form and include original signatures from each; signature order does not matter. If the authors 
are not able to agree among themselves on authorship changes, please withdraw the paper. The 
Editor and Editorial Office do not choose to arbitrate such debates. Authorship changes can not 
be submitted with proof changes. The publisher is not authorized to make such changes and it 
will delay the publication of your manuscript 
 
CANCER CLASSIFICATIONS  
We encourage authors to use the American Joint Commission on Cancer TNM Classification 
scheme when describing patients with ophthalmic malignancies (American Joint commission 
on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.) This 
classification scheme can also be found at http://www.cancerstaging.org/mission/whatis.html 
 
CASE REPORTS  
Ophthalmology almost never accepts case reports as stand alone manuscripts.  Sometimes we 
do accept full manuscripts for example, a detailed clinical pathologic review.  Please share 
case reports with us using the "letter to the editor" format.  Although not encouraged, any 
images, tables will be online only supplemental materials. In the letter, briefly explain what is 
novel, unique, or new, and please concisely summarize your literature review strategy that 
allows you to make the "new/novel/unique" claim.  Letters are reviewed and case reports 
using the letter format will be considered.  Copyrights and ICMJE conflict of interest forms 
are required from all authors. 
 
CLINICAL TRIAL REGISTRATION 
As of July 1, 2006, the Journal requires reporting of clinical trial registration in all submitted 
trial-related manuscripts. Human clinical trials beginning enrollment on or after March 1, 
2006 should be registered prior to enrollment.  Please state in the methods section of the 
manuscript that this was done and where the registration information is publicly available.   
 
The Editor expects that phase 3 trials will be registered and many phase 2 trials are 












Satisfactory public databases include the NIH’s at http://www.clinicaltrials.gov/ and the site 
from the International Standard Randomized Controlled Trials at http://www.controlled-
trials.com/  
 
For additional information, please consult:  
Registration of Clinical Trials, Leonard A. Levin; Justin L. Gottlieb; Roy W. Beck; Daniel M. 
Albert; Thomas J. Liesegang; Creig S. Hoyt; Andrew Dick; Robert Bhisitkul; Andrew P. 
Schachat, Arch Ophthalmo 2005;123:1263 -4  
 
The International Committee of Medical Journal Editors (ICJME) has information at 
http://prsinfo.clinicaltrials.gov/icmje.html 
 
Our policies are intended to be very similar to those of The Journal of the American Medical 
Association (JAMA) and The New England Journal of Medicine (NEJM).  The JAMA policy 
can be viewed at http://jama.ama-assn.org/misc/authors.dtl. The NEJM summarizes their 
policy in two editorials: Is this Clinical Trial Fully Registered? N Engl J Med 2005;352:2436-
8 and Clinical Trial Registration: A Statement from the International Committee of Medical 
Journal Editors N Engl J Med 2004;351:1250-1 
  
CONFLICT OF INTEREST (COI)  
Every author must complete a copy of the ICMJE Potential Conflict of Interest Form and 
submit it to the corresponding author noting if any commercial connection between that 
individual author and the topic may be suspected.  Each author is expected to disclose any 
type of financial interest that is related to the manuscript.  Mutual funds need not be 
mentioned. Such disclosure will not affect the review of the manuscript. 
For further insight, please refer to Liesegang TJ, Schachat AP. Enhanced Reporting of 
Potential Conflicts of Interest: Rationale and New Form (Editorial). Am J Ophthalmol 
2011:151(3): 391-393. 
 
As of January 2012, all submissions must have the ICMJE Conflict of Interest Form 
completed and uploaded for each author preferably as part of the initial submission 
process, but absolutely no later than first revision.   The form posted on the ICMJE Web site 
(http://www.icmje.org/coi_disclosure.pdf) and enclosed in our guide as a downloadable form 
includes instructions to help authors provide the correct information.  For nonnative English 
speakers, there is a glossary of the terms used in the form.  Guidelines for translation of the 
form’s instructions into multiple languages is planned, recognizing that some nuances may not be 
understood or well known in some cultures.1  
 
Authors can download the form from either previously mentioned location, add the requested 
information, and save the completed form on their computer. The completed form can then be 
sent to the corresponding author to be uploaded during the submission process.  Over time, more 
journals may request the identical document, which will simply need to be updated by the authors 
in relation to the current manuscript prior to uploading.  The corresponding author will list any 
disclosures on the cover page of the submission as well as financial support for the work, if any. 
 
Every published manuscript will have a blanket statement, inserted by the publisher, within the 
abstract box.; either "None of the authors have any conflicts of  interest to disclose." OR "Authors 
with financial interests or relationships to disclose are listed after the references."  Corresponding 
authors will be asked to confirm or update conflict of interest statements as part of the final steps 












Ophthalmology will be vigilant in the quest to ensure that the public continues to trust that the 
medical literature and our authors are not inappropriately influenced by their financial 
relationships with industry or other prejudices. If allegations arise, the journals must and will 
react.2 
1. Drazen JM, de Leeuw PW, Laine C, et al. Toward More Uniform Conflict Disclosures. The Updated ICMJE
Conflict of Interest Reporting Form. N Engl J Med 2010;363(2):188-9.
2. DeAngelis CD, Fontanarosa PB. Resolving unreported conflicts of interest. JAMA, 2009;302(2):198-9
COPYRIGHT ASSIGNMENT FORM  
Start circulating copyright forms among authors early so they are completed in time for 
submission. As of January 2012, copyright(s) must be uploaded into the system 
preferably at first submission but no later than first revision.   
The method of submitting your copyright form(s) is to upload it with your manuscript.  We 
suggest the corresponding author collect all signed copyrights and submit them with the initial 
manuscript submission or, if absolutely necessary, when submitting a first revision to the 
editorial office.  We ask that the corresponding author coordinate this effort to be sure each 
form is done correctly prior to submission to the editorial office.  Type in the agreed upon title 
and author order on the top of the copyright form(s), print out the form.  Every copyright 
submitted for a given manuscript must have identical and complete information at the 
top of the form where the title and author lines are.  You can then circulate for signature 
one or more copies of this form for all authors to sign.  Once original signatures are obtained 
from all authors, scan the form(s) (preferably to PDF format) and upload them at submission 
time  
The copyright form signed by each author states that you either own the copyright, or have 
written permission to use all the material in your article.  If you are submitting any material to 
which you do not own copyright, please secure permission to use the copyrighted materials.
NOTE:  Once a manuscript has been submitted, the order of authorship (including adding or 
removing authors) CAN NOT be changed without a written request to the Editorial Office 
from the corresponding author.  This request must include a statement signed by all authors 
that they are in agreement with the change along with a new copyright form, both signed by 
all authors.  Specifically, if an author is removed, a letter from that author agreeing to his/her 
removal is required. The new copyright form must show the title and authors’ names in the 
order they should appear in print on the top of the form and include original signatures from
each; signature order does not matter.  If the original authors are not able to agree among 
themselves on authorship changes, please withdraw the paper.  The Editor and Editorial 
Office do not choose to arbitrate such debates. AUTHORSHIP CHANGES CAN NOT BE 
SUBMITTED WITH PROOF CHANGES.  The publisher can not approve such changes and 
it will delay the publication of your manuscript. 
COVER FIGURES   
Ophthalmology publishes color photographs and images on the cover of the printed journal. The 
Cover Page Editor for the journal is James D. Brandt, M.D. of the University of California, Davis. 
Our cover pages are usually generated from figures in articles appearing in a given issue, but our 
criteria are that images considered for the cover be visually striking and technically excellent (and 
fit on the cover layout). In case there are no appropriate images among the articles slated to 











clinicians for consideration. These pictures don’t need to be something rare – our goal is to find 
technically excellent and striking images that make the reader look at the cover and say ‘wow’. 
So a gorgeous image of a common ophthalmic finding is just as welcome as a photo of something 
rare. Square or portrait (vertical) format images work best, as they can be laid out with space for 
the text box announcing issue highlights along with room for the mailing label along the bottom. 
Composites of several photographs (e.g., a sequence over time or a comparison of color 
photography with angiography, pathology, etc.) also work well and provide flexibility in layout. 
To submit an image for consideration as a future cover, Dr. Brandt is happy to take a look at 
images sent to him by e-mail (jdbrandt@ucdavis.edu); please use the subject header “Cover 
Image for Ophthalmology” so that your e-mail is appropriately flagged. Send Dr. Brandt a JPEG 
version of your image along with a brief description of the case (a one sentence description is all 
that is run with the photo in the Table of Contents) and the names and institution of the 
clinician(s) and photographer(s) responsible for the image (limit of two each). If it is determined 
that the photograph is appropriate, he will work with you to generate appropriate file(s) for 
publication (see technical considerations below). 
If your image is selected for use as a potential cover image, Ophthalmology will need a completed 
copyright transfer form (see downloadable forms.)  Once the form is received, the Editorial Office 
will put the image in queue for a future issue. Cover images submitted by photographers and 
clinicians in this manner are used for covers only two to four times a year, so even if we 
determine that your image is appropriate for a future cover, it may take a year or more before it 
would appear in print. 
Technical Considerations
The four color printing process used in producing the journal cover requires the highest resolution 
files to achieve the best quality. Should your image be chosen for the cover, the file(s) should be 
available as minimally compressed JPEG or ideally uncompressed (e.g., TIFF or PSD) high 
resolution files of at least 8"x8" at 300 dpi. Screen grabs from video (even high definition video) 
do not upscale adequately for print and look quite blurred in print; similarly, output from most 
diagnostic instruments do not upscale well and can look very pixelated with ‘jaggies’ on a cover. 
The only exception to this is when images from video or diagnostic instruments are reproduced as 
part of a composite – smaller images can reproduce well, and Dr. Brandt will work with you to 
see if adequate quality can be achieved in this manner.  
Please do not perform any post-processing of the digital image other than light dusting and spot 
removal. sRGB colorspace is fine; do not convert to CMYK, as this will be done by the publisher 
during pre-press processing.  The high resolution files for final publication are usually too big to 
send by e-mail. You can use a free web-based large file transfer service (e.g., 
www.yousendit.com) or mail a CD to Dr. Brandt. 
Copyright Considerations 
Copyright for the image(s) must be transferred to the American Academy of Ophthalmology. The 
copyright transfer form must be signed by all the listed authors. Please note that if the image has 
already appeared as part of an article in another journal or in a textbook, you probably do not 
have the right to transfer the copyright to the AAO. If the image has appeared as part of 
photography contest (and especially if it won a prize), please check the conditions of your contest 
participation – you may have signed away the right to submit the image to Ophthalmology. 











DRUG and EQUIPMENT MANAUFACTURER NAMES 
 
Drug names 
Do not use drug trade names in titles. In the abstract use the generic name, but include the trade 
name once, in parentheses, after the first use of the generic name.  In the text, use the generic 
name, but include the trade name once, in parentheses, after the first use of the generic name. 
 
Device/Equipment Names  
The device name is permitted in the title, abstract and text. However after the device has been 
identified at first use in the abstract and text, thereafter refer to it gene rically.  In th e case of 
equipment, include the m anufacturer’s name, city, state and/or country parenthetically at the 
first use in the text.  
 
EDITORIALS  
General:  A two-page editorial is usually published in each issue of Ophthalmology.   
Editorials are generally solicited by the Editor- in-Chief, although unsolicited submissions 
will also be considered.  
 
Editorials may deal with clinical or non-clinical topics in summary form and must not exceed 
1400 words, including references.  Often editorials are linked with a particular manuscript 
awaiting publication and, therefore, adherence to deadlines is critical and mandatory.   
Although discouraged, if a figure is absolutely necessary, decr ase the word count by 
approximately 200.      
 
Submission:  The text of the editorial, a signed copyright(s) and ICMJE conflict of interest 
form(s) need to be submitted – you can add anything you wish the editor to know in the “enter 
comments” section of the submission process.  Figures are generally not included or 
encouraged in these types of submissions.  If figures are used please submit following the 
same criteria for manuscripts outlined above.  Most likely they will be online only 
supplemental materials. Copyright form(s) and ICMJE conflict of interest form(s) should be 
uploaded with initial submission but must be uploaded no later than first revision.      
 
Process:  Editorials undergo peer review re gardless of whether they are solicited or 
unsolicited subm issions.  Once received, an Edito rial is assigned a num ber of which the  
author is advised.   The pape r will go through the usual review  process, often with som e 
specific insight or guidelines offered to reviewers by the Editor.  The author is then advised of 
any changes which need to be m ade and refere nces are checked.  Upon return of the revised 
paper, the editor gives his approval and it goes to the publisher.   
 
ENGLISH EDITING ASSISTANCE  
Members of the (United States) Council of Biology Editors (and others) have expressed 
interest in helping authors of manuscripts submitted to Ophthalmology with English editing. 
Authors may contact these individuals or services directly by mail, phone, fax, or e-mail. All 
financial arrangements are strictly between the two parties. Ophthalmology neither endorses 
nor recommends any specific individual or service. The Journal office may return a 
submission and recommend professional editing prior to review. Professional editing, while 
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EVIDENCE BASED STUDIES – ADDITIONAL GUIDELINES 
The journal is eager to receive evidence-based studies.  These papers incorporate a systematic 
review of the literature and summ arize clinical recommendations using the structured format
outlined below.  Authors interested in submitting these manuscripts are encouraged to
correspond with the Editor-in-Chief in advance to be sure that the topic is of interest. The 
main text of  these articles will conclude with  summary recommendations for testing or
therapy of  the clinical problem  discussed. Each recommendation will include author-
designated and peer reviewed ratings displayed in superscripts (see definitions below)
indicating the im portance of recommendations to clinical outcome (A, B, C) and the overall 
strength of evidence of supporting literature (I, II, II I). The strength of evidence ratings will 
be based on author judgment as to the quality and validity of the existing fund of peer-
reviewed or other published literature. Authors and co-author methodologists with special 
expertise in the topic may be recruited by the Journal Editor to write these summary updates.  
Authors will be expected to conduct thorough  literature s earches (sys tematic reviews) of 
national and international peer-reviewed publications utilizing availabl e databases and other 
sources as necessary. In many topic areas no rec ent high-quality studies may be available, in 
which case the discussion should emphasize to clinicians what studies are needed and the 
inadequacy of the evidence that justifies current management. 
Completed articles will be reviewed using th e usual Journal peer-review process, including 
author-assigned ratings for the im portance of  clinical recommendations and the strength of  
supporting evidence. Publication may be scheduled, after revisions as in dicated through peer-
review, and  articles will be placed  in regular forthcoming issues at the discretio n of the 
Editor-in-Chief.  
Definitions of Superscript Ratings: 
Superscript ratings for clinical recommendations: 
"A" indicates that the recomm endation is cons idered very im portant or crucial to a good 
clinical outcome  











"C" that the recommendation may be relevant but cannot be definitely related  to clinical 
outcome. 
Superscript ratings for peer reviewed or other cited evidence:  
 “I” indicates strong evidence in support of the statement. In general, the study or studies cited 
used designs which allowed the issue to be addressed, were perform ed in the population of  
interest, were executed in a m anner to produce reliable and accurate data, and were analyzed  
using appropriate statistical methods. The study or studies produced either statistically 
significant differences between control and experimental groups  or showed no statistically 
significant differences, despite a design, which had high statistical power to detect differences 
and/or narrow confidence limits on the parameters of interest.  
Strong evidence includes we ll-done randomized controlled clinic al trials designed to address 
the issue in question, especially reg arding the e fficacy of treatm ent or the superiority of one
treatment over another. Well-done meta-analyses (retrospective reviews of previously 
published randomized controlled trials) may also constitute level “I” supporting evidence.  
“II” indicates there is substantial evidence in support of the statement but the evidence lacks 
some qualities, thereby preventing its justifying the statement without qualification. 
Deficiencies might include unavailability of well-done randomized tr ials, or studies lacking 
other elements of high-quality  evidence such as adequate control groups, sufficiently long 
follow up, good compliance with therapy, or acceptable loss to follow up.  
Nonrandomized com parative trials involving sufficient subjects to demonstrate statistically 
significant differences between study and control groups might provide strong evidence for 
the efficacy  of a therapy. Noncomparative case series or case reports might be justifiably
included as strong evidence for linking complications or adverse events to a specific therapy 
without stating the probability of their occurrence.  
Observational studies, including control groups such as Cohort studies and Case-control 
studies, might provide strong evidence for or against therapy in terms of longitudinal data
about disease natural history, outcome of therapy, adverse events, or specific anatomical or 
functional outcomes. Well-done cross-sectional studies might provide strong evidence for the 
importance of the clinical problem. Well-done systematic literature reviews or meta-analyses 
might also provide moderately strong evidence for or against a test or therapy.  
Even an otherwise well-done randomized controlled trial dealing with the issue of  interest 
might have been performed using too select a population and may not be clearly applicable to 
a broader population of interest, or it might have produced only marginally statistically 
significant differences between control and experimental groups. A large consecutive case  
series might also fit in to this category if  it  compares outcome only to  a historical control 
group from the same clinical setting.  
 “III” indicates a weak body of evidence insuffi cient to provide support  for or against the 
efficacy of a test or therapy and  would generally apply to panel consensus o r individual 
opinions, small noncomparative case series, and individual case reports. Non-com parative 
studies (without controls), cohort studies with variable follow up across the patient population 
studied, retrospective chart reviews with missing data, or even randomized controlled trials 
evaluating highly subjective outcome data would be examples of weak forms of evidence. 
Authors of evidence-based manuscripts should follow the guidelines outlined in the 












Title Page - The title should clearly describe the main topic and indicate the manuscript is an 
evidence-based summary. (Example: Management of nonsymptomatic retinal tears and lattice 
degeneration: an evidence-based summary.) The title should include the phrase: evidence-
based review or evidence-based update.  
 
Précis - The précis should indicate what new insight the article offers or what principal 
controversy persists. 
 
Structured Abstract   Abstracts for evidence-based manuscripts must be limited to 250 words 
and include the following five sections: 
1. Topic: identify the specific clinical problem and therapy to be evaluated.  
2.  Clinical relevance: characterize the magnitude/importance of the problem/disorder and 
define the current standard of care.  
3.  Methods/literature reviewed: describe the sources of peer-reviewed materials utilized and 
dates of publication. 
4.  Results: summarize the materials identified and obvious contrasts with prior and current 
standards of care. 
5.  Conclusion: summarize the strength of evidence for the recommended therapy or test. 
 
Text - The text should utilize standard Journal formatting as described in Ophthalmology's  
Instructions for Authors and be divided into five distinct sections:  
  
1.  The introduction/background (unlabeled) should clarify the magnitude of the clinical 
problem, (prevalence or incidence) and provide perspectives on the importance of its 
management to patient well-being and quality of life.  
 
2.  The Sources and Methods of Literature Search (titled) should identify the databases and/or 
specific journals searched and the dates of publication. The methodology of the literature 
search, including criteria utilized for selection and inclusion, should be listed insufficient 
detail to permit   duplication of the effort. If only poor quality supporting evidence exists, 
author comments should emphasize this in the discussion, in addition to assigning appropriate 
overall ratings for the strength of supporting literature. 
 
Suggested sources for literature searches include, for example, PubMed 
(http://www.pubmed.com) and Medical Matrix (http://www. medmatrix.org).  
 
The Cochrane Library is an additional excellent source of high quality reviews of 
general medical information, systematic reviews, and meta-analyses, including some 
eye topics (http://www.cochranelibrary.com).  
 
3.  Summary of Evidence (titled) should summarize the findings in text or tables. 
 
4.  The Clinical Recommendation(s) (titled) should be listed in order of importance, and each 
separate recommendation accompanied by bracketed superscripts "A,""B," or "C," indicating 
the author's impression as to its importance to clinical outcome. Superscripts "I,""II," or "III" 
will also be used to indicate the author's judgment about the overall (average) veracity of 
supporting literature. When appropriate, recommendations should include typical clinical 
scenarios. (Example of clinical recommendation and author-designated superscripts: A 
symptomatic superior horseshoe retinal tear with a cuff of surrounding subretinal fluid should 











crosschecking with AAO products (PPPs, Pro-Vision Series, Focal Points, Basic and Clinical 
Science Course Books) to avoid or acknowledge inconsistencies in clinical recommendations. 
5. References should be limited to the highest quality studies available, regardless of the
study type.  One set of complete copies of all cited references should be included. Duplicates
will be sent to peer reviewers upon request. For reference formatting examples, please go to
References and Reference Style Guide
FIGURES (illustrations, graphs, photos for all submission item types)
Whether submitting individual images or a composite, please note the artwork guidelines that
follow.  Figures will be included in the final PDF but the figure file names will not be visible 
to reviewers. Figures, that are not a composite, should be loaded to individual files and clearly 
identified. For all figures the figure number must be entered in the file description field 
before the figure is uploaded.  This can be done on the "attach files page" by choosing 
"figure" in the pull down menu. Below it there is the “Description” box; enter the figure 
number to the right of the word "Figure" before opening and attaching each figure file. Do not 
enter legends here, just the figure number.  For linear art created by MSOffice or similar type 
software, the figure number should also be typed on the figure page. 
The Journal may provide one page of color illustrations per calendar year for each first author 
without charge, at the discretion of the Editor-in-Chief.  The criterion generally used is 
whether the color illustration best conveys the information being illustrated.  Additional color 
pages may be published at the author’s expense.  Formatting requirements may lead to 
illustration placement on more than one page, although we try to avoid this as much as 
possible.  The cost varies from $650 to $1200 per additional page and you will be advised of 
the cost when you receive your proofs. 
If a manuscript has been reviewed and accepted with color photos, it must be published with 
color photos.  The author is responsible for page charges for color photos that occupy more 
than one page, and cannot opt to have them printed in black and white without the permission 
of the journal office.  Please check with the Journal office or the publisher for information. 
Clinical photographs (including those generated electronically from machines such as MRIs, 
fluorescein angiography, visual fields, etc.) must be masked to prevent identification of the 
patient.  Clinical photographs that permit identification of an individual (those exposing 
anything more than just the eyes) must be accompanied by a signed statement by the patient 
or guardian granting permission for publication of the pictures for educational purposes.  All 
graphics, including composites (such as clinical photographs, fluorescein angiography, CT, 
MRI, x-ray, photomicrographs, etc.) should be submitted at the actual size that they would be 
presented in the journal, 100 % of their print dimensions so that no scaling is necessary, but 
remember that very few pictures are full page pictures. The width should be no more than 7 
inches.    
. The publisher will not re-draw or rework your photographs or illustrations.  Submit all figures 
in the order they appear in the legends.  If there are six or more color pictures, a composite 
maybe preferred so they fit on a standard journal page and potentially decrease your color 
figure costs.  However, be sure to do this only if the quality of what you are attempting to 
portray with the figures is not compromised. The completed composite must meet the 
guidelines for artwork submission.  Composites must also be labeled using typed text in a 
corner of the each image. Composite are encouraged for multipanel figures (e.g., Fig 1A, 1B, 





















 TIFF YES YES  YES YES YES 
 WORD FILE YES YES  NO NO NO 
 PDF  FILE YES YES  NO NO NO 
 COL OR 
MODE IN 
PHOTOSHOP 
BITMAP RGB  GRAYSCALE RGB 
 RESO LUTION 
(PIXELS/INCH) 
150 300** 600 
(will be large file size) 
300 300 
 TYPICAL FILE 
SIZE 
Less than 2MB No larger than 
10 MB 
Can be as large 
as 60  MB 
More than 
10 MB 
5 to 15 
MB 
 
* Line art can be submitted in the original file format that it was created (e.g., Word, Excel, 
PowerPoint, etc.) 
** If very little or no text – otherwise, print to a PDF  
 
General 
 The physical dimensions of any artwork must fit within the dimensions of the pages 
within the Journal.  (i.e., width no more than 7 inches) 
 Be consistent in the font type and size used in the artwork. 
 Artwork must use recomm ended nam ing conventions.  Som e exa mples include 
fig1.tif (figure 1 in TIFF format). Always ensure that the file extension is present to 
ensure quick and easy format identification. 
 
We have upgraded our electronic submission system. You may now choose to load each 
figure file individually or to take all the individual figures files and zip them into a single zip 
file, which will reduce the size of your upload (and hence the time) it takes to upload your 
files and complete your submission.  This does not mean you can load everything in one file – 
each piece needs to be in a separate file and those individual files can then be zipped and 
uploaded.  The system will unzip them for you. 
 
If you choose to upload a ZIP file, compress the files needed for your submission or revision 
using a ZIP program, such as WinZip or StuffIt (free trials of these are available online). Use 
the Browse button to find the zipped file and then click on the Attach button to upload it. As it 
loads, it will unzip automatically within the system. Then using the drop down menus and 
description fields to the left of the file names, select the appropriate items and type in the 
correct descriptions, E.G. Figure, then Figures 1A through E. 
 
FINANCIAL SUPPORT  
Identify all funding sources, public and private.  On the title page please state “Financial 
Support:  None” or provide the agency name and city, company name and city, fellowship 
name, and grant number. If there is financial support, please provide also one of the two 
following statements:  “The sponsor or funding organization had no role in the design or 
conduct of this research.”   
OR “The sponsor or funding organization participated in (list those that are appropriate: the 
design of the study, conducting the study, data collection, data management, data analysis, 
interpretation of the data, preparation, review or approval) of the manuscript.” 
 
IN PRESS/ONLINE RELEASE 
As of September 1, 2007, manuscripts are automatically available on line as "in press" articles 











produced after all editorial and author corrections are made; however there is a disclaimer in 
case a critical error is found. No routine editing will occur once this is online. The “in press" 
version is not meant to be a last editing opportunity for authors, however if a major, critical 
error is found we may be able to make corrections prior to publication or an erratum will be 
published in a future issue. This "in press" version is removed as soon as the monthly issue is 
available online.  
It is the corresponding author's responsibility that all editing be done at the time the original 
proofs are received from the publisher and that the publisher is notified immediately if the 
authors do not wish to have the "in press" article released online. All notifications regarding 
proof approvals, proof corrections or requests that an article not be released "in press" prior to 
publication must come from the corresponding author to l.traynor@elsevier.com. 
INSTITUTIONAL REVIEW BOARD/ETHICS COMMITTEE APPROVAL (IRB) 
If the study being reported involved human subjects, human derived materials, or human 
medical records, please include one of the two following statements in the Materials/ Patients 
and Methods section:   Institutional Review Board (IRB)/Ethics Committee approval was 
obtained   OR  IRB/Ethics Committee ruled that approval was not required for this study. 
LEGENDS 
Figure legends (photos, drawings, graphs) should  follow figures. Figures m ust be num bered 
consecutively as they appear in  text. Histological figures, stains and magnifications should be 
noted in the legends. Any figure that has been published elsewhere should have an 
acknowledgment to the original source; a copy of the release to publish the figure, signed by 
the copyright holder, must also be submitted. Legends must identify all symbols, 
abbreviations, acronyms or letters that appear on  the prints.  Table legends should be within 
the table.  All abbreviations in each table must be defined even when repetitive to each other.  
LETTERS TO THE EDITOR AND ASSOCIATED REPLIES
General:   Letters to the Editor should be concise comments focusing on an article published 
in the Journal within the last six months. The letter should offer alternative perspective, 
elucidate a flaw in methodology or a perceived misinterpretation of data, addressing no more 
than two major points.  The letters should start with “Dear Editor” and the article being 
commented on should be referenced in the first paragraph of the letter.  Gratuitous comments 
such as “… I commend the author for their fine study” or overly critical remarks are not 
necessary or appropriate.  Letters should end with the name, degree and location(city, state or 
city, country) for each author.  For example Andrew P. Schachat, MD, Cleveland, Ohio.  
Format:  Letters should be limited to 700 words, double-spaced and no more than five references.  
Please note that letters do not have tables or figures published but they are put up as online only 
supplemental material. The figures or tables will not appear in the printed version but will be 
archived with the online version on the publisher's website 
www.ophsource.com/periodicals/ophtha and accessible through Medline and other online 
databases. Therefore, in the appropriate location where you mention your table, graph, figure or 
chart please insert "(available at http://aaojournal.org).”   Although figures (photos, charts, 
graphs, tables) are not included in publication, the online version needs to conform to the same 
requirements regarding legends and identifying all abbreviations in each figure.  
Submission:  The text of the letter, a signed copyright(s) and ICMJE conflict of interest 
form(s) need to be submitted. These should be uploaded into the system with your initial 











section of the submission process.  The title should be limited to 40 characters.
Process:   Upon receipt, a letter to the editor is reviewed by the Editor in Chief, and, in some 
instances, by outside reviewers. If the letter is to be accepted for publication, it is forwarded to the 
corresponding author of the article which it addresses for the opportunity to respond. If the 
invitation is accepted, both letter and reply are edited and reference checked and published 
together.  If the invitation to reply is declined the original letter will be processed and published 
by itself. The titles of all letters are limited to 40 characters.  If needed, the Editor will create titles 
to fit this limit.   
When the journal office receives a Letter to the Editor addressing an article, the corresponding 
author of the article being discussed usually will receive an email entitled “Invitation to Reply 
to a Letter to Editor”.   It is imperative that you log onto the system as an author and accept 
this invite immediately and then upload and submit your reply letter within 21 days to the 
Editorial Office.   
Occasionally, you may be told by the Editorial Office that a manuscript is rejected but the 
option to reformat and resubmit it as a letter is suggested.   This can only be done at the 
Editor’s discretion.  If you decide to reformat your paper as a letter, you should send it as a 
new, separate submission. In these scenarios only, WHEN UPLOADING, USE THE “MS TO 
LTR” SELECTION AS THE TYPE OF SUBMISSION.  Also be sure in the “Additional 
Comments” section to advise us of the manuscript number of this original paper you are 
reformatting so we can make reference to it if necessary.   All other Letter to the Editor 
guidelines (700 words, double-spaced, etc) apply including the need for a copyright and 
ICMJE conflict of interest forms to be uploaded.    
LITERATURE REVIEWS
Literature reviews have great teaching value, but the focus of Ophthalmology is on "new" 
material.  Reviewing the past literature tends not to add "new" information to the current 
literature.  But, if you incorporate new knowledge into the review by aggregating past information 
to create new knowledge, such reviews are considered.  For example, a metanalysis combines old 
data in a way that teaches new knowledge.  Better literature reviews tend to be highly structured 
with inclusion and exclusion criteria for which papers will be included and they involve more 
than, e.g., "we searched PubMed on 'cataract'."  There is excellent information on metanalyses 
and structured and methodical literature reviews available at the Cochrane Collaboration website 
(cochrane.org).  In addition, the Journal will consider and may accept so called "evidence-based" 
reviews.  There are detailed instructions in this Guide for "evidence based studies – additional 
guidelines." 
MANUSCRIPT TEXT FORMAT 
Double space the entire manuscript after the title page.  Line numbering will be automatically 
inserted into your manuscript text file by the system when it builds the PDF. The average 
published manuscript in Ophthalmology, including references, is up to printed 6 pages in 
length. This corresponds, depending on font size and printing, to between 16-20 pages of 
double-spaced draft.  
1. Title Page
The title page should include the following information.
a) Title: The title should be meaningful and as brief as possible.  No longer than 135 characters,











those approved in Abbreviations. Please do not include any lecture titles or award titles in the 
manuscript title. Recognition of such can be made with an asterisk at the end of the title and 
the award/lecture noted in the footnotes. 
b) Authors: Provide first name, middle initial, last name and no more than two advanced
degrees or professional certifications. The Journal does not print society affiliations.  Also
indicate each author's affiliation during the course of the study in footnotes on the title page
using superscript numbers, not symbols (e.g., Ronald Smith1).  Specifically identify the
corresponding author.
Please carefully review the very extensive “Authorship” section of this guide.  It carefully 
addresses authorship criteria, group/writing committee authorship, guest authors, ghost 
authors, corresponding authors and related responsibilities, numbers of authors, and entering 
authors into the system. 
c) Meeting Presentation:  If the material is under consideration for presentation or has been 
previously presented, supply the name, place, and date of the meeting. (e.g., the American 
Academy of Ophthalmology Annual Meeting, November, 2003).  This is especially important 
for AAO Meeting papers as we have first right of refusal on these papers. 
d) Financial Support: - Identify all sources, public and private.  On the title page please state 
“Financial Support:  None” or Provide the agency name and city, company name and city, 
fellowship name, and grant number.  If there is financial su port, please provide also one of 
the two following statements: “The sponsor or funding organization had no role in the design 
or conduct of this research.” 
 OR  
“The sponsor or funding organization participated in (list those that are appropriate: the 
design of the study, conducting the study, data collection, data management, data analysis, 
interpretation of the data, preparation, review or approval of) the manuscript.” 
e) Conflict of Interest: - A blanket statement that “no conflicting relationship exists for any 
author” is requested on the title page, if appropriate.  Otherwise, the corresponding author 
should summarize the disclosures sent to him by each author and upload the ICMJE form of
each author as well. (See detailed conflict of interest section above.)  Either way ICMJE 
conflict of interest forms must be uploaded from every author. 
f) Running head:  The running head, also known as the short title, which appears on the top of
each right hand published page of your manuscript, should be no longer than 60 characters.
g) Address for reprints
2. Abstract – see separate “Abstract” section
3. Text
a. Introduction:  Without a heading, the introduction should refer only to the most pertinent
past publications and should not be an extensive review of the literature.
b. Intervention or Methods or Testing:  This section should be written with sufficient detail to












  FOR HUMAN SUBJECTS:    
 
 Informed Consent - Manuscripts reporting the results of experimental investigation 
on human subjects must include a statement to the effect that informed consent was 
obtained. 
 HIPAA - For studies conducted in the United States a statement that the work is 
HIPAA-compliant is required (See Ophthalmology 2003; 110:1074-5.)  
 IRB/Ethics Committee - Human subjects/materials/medical records -  If the study 
being reported involved human subjects, human derived materials, or human 
medical records, please include one of the two following statements in the 
Materials/ Patients and Methods section:  
 
                       Institutional Review Board (IRB)/Ethics Committee approval was obtained 
                                      OR 
      IRB/Ethics Committee ruled that approval was not required for this study.   
 
 Declaration of Helsinki  - A statement is required that described research adhered to 
the tenets of the Declaration of Helsinki 
 Clinical Trial Registration – A statement should be provided in the methods section 
of the manuscript that this was done and where the registration information is 
publicly available. (see Clinical Trial Registration for more detailed information)  
 We encourage authors to use the American Joint Commission on Cancer TNM 
Classification scheme when describing patients with ophthalmic malignancies 
(American Joint commission on Cancer. AJCC Cancer Staging Manual. 7th ed. New 
York, NY: Springer; 2009.) This classification scheme can also be  found at 
http://www.cancerstaging.org/mission/whatis.html 
 
  FOR ANIMAL SUBJECTS:     
 
If animals were used in a study, the notice of approval by the appropriate Institutional 
Animal Care and Use Committee should be included in the methods section of the 
manuscript.   
 
 
c.  Results:  Results must be concise. 
 
d. Discussion: The discussion should be restricted to the significant findings   presented.  
Digressions and theorizing are not appropriate.  NOTE: Discussion is the final section of a 
manuscript.  Please do not insert a conclusion section; only the abstract has a conclusion 
section. 
 
ONLINE ONLY PUBLICATIONS    
Some manuscripts are not accepted due to lack of space rather than lack of science and in 
some cases an author may be given an option of having their entire  manuscript printed 
“online only.”  If the Editor deems it appropriate, you will be given the option of having your 
manuscript published online only.  There will be no printed version of this manuscript BUT it 
will appear in the table of contents under a new section called “Online Only Publications”1 
and it shall be citable just like any other online resource.  We are told that Pub Med and other 
similar databases will pick it up as an online citation.  Submission guidelines are the same as 
they would be for acceptance in the print edition.  Color figures in an online only publication 












ONLINE SUPPLEMENTAL MATERIALS   
Space in Ophthalmology is highly competitive and sometimes good manuscripts or data 
cannot be published due to space limitations.  For articles that ARE ACCEPTED for 
publication in the journal but whose authors have agreed to cut back on the amount of 
material provided due to space considerations, we now offer online only supplements to 
printed articles. Such supplements will generally include tables, charts, figures, etc. that 
would further enhance a published article but for which there is insufficient room in a given 
issue to print it.  The availability of this additional information will be noted in the Table of 
Contents by an icon.  The information will not appear in the printed version but will be 
archived with the online version on the publisher's website 
http://www.ophsource.com/periodicals/ophtha and accessible through Medline and other 
online databases.  In the printed manuscript, on the cover page and in the appropriate, 
corresponding section of your text, there will be a notation that “Supplemental materials are 
provided at the end of the online version of this manuscript”.  
If you opt for an online supplement, add a reference to it in parenthesis after the mention of 
the information to appear online: For example, “…as shown in Table N (available at 
http://aaojournal.org).”  Online tables or figures should be numbered consecutively as they 
appear in the text, in the same sequence as printed figures or tables.  Also, add a statement to 
the title page that should read similar to: “This article contains additional online-only material. 
The following should appear online-only: Figures X, Y, Z and Table N.” The materials will 
not appear in the printed version but will be archived with the online version on the 
publisher’s website http://www.ophsource.com/periodicals/ophtha and accessible through 
Medline and other online databases.  
In some cases, when the Editor decides there are too many figures, tables or other 
supplemental information (e.g. study group listings) to publish in print, an author may be 
given the option of providing a PDF of  the item(s) for online only release versus removing 
them completely from the submission..  These are not proofed or edited in any way by the 
publisher thus eliminating cost and not counting to a limited budget of online only 
supplemental pages.  These figures need to have their legends included in the figure file along 
with the figure number.  
All supplemental materials must follow the same rules and regulations as if they were to 
appear in print.  For example, tables must be able to stand alone with all abbreviations, 
references, etc. identified.  Table legends would include definitions for the abbreviations, if 
any.  Color figures that might appear online only are at no cost to the author. 
PERMISSION TO USE COPYRIGHTED MATERIALS 
Permission to use materials published in Ophthalmology: 
Permission requests should be submitted to: Elsevier Health Sciences Rights Department, 625 
Walnut Street, 3rd  Floor, Philadelphia, PA 19106-3399. Tel: 215.238.7869 or, 800.523.4069, 
ext. 7869 Fax: 215.238.2239 Email: healthpermissions@elsevier.com  
Authorization to photocopy items for internal or personal use or the internal or personal use of 
specific clients is granted by the American Academy of Ophthalmology, Inc.  [This applies to 
libraries and others registered with the Copyright Clearance Center (CCC) transactional 
reporting service provided that the base fee of $20 is paid directly to CCC, 222 Rosewood 












Permission to use materials to which others hold copyright in your submission to 
Ophthalmology  
The copyright form that you si gn and submit with your manuscript states that you either own 
the copyright, or have written permssion to use, all the material in your article.  If you are 
submitting any m aterial to which you do not own copyright,  please secu re permission from 
the copyright holder to publish or reprint this material.  Examples of such materials could be a 
clinical image/chart that was published in anot her ophthalmological journal or in a book or a  
photo of an ophthalmic device that you obtained from a pharmaceutical company.  In most 
cases, permission can be easily obtained by e-mailing the publisher or company and 
explaining specifically what you want to use, where (print and online versions of 
Ophthalmology) and why (in my article entitled XXXXX.)  Most copyright holders will rep ly 
with a “permission granted” letter which you should upload along with your submission.   
Give yourself ample time to request and receive permission, usually 3-6 weeks 
 
PRÉCIS    
 All manuscripts must include a précis of 35 words or less summarizing the main 
finding/outcome of the study. The précis should not duplicate the abstract co clusion.  Please 
respect the 35-word limit as formatting requirements lead to strict application of the word 
limit.  If the paper is published, the précis will appear under the title in the Table of Contents.   
The précis is submitted as a separate file and should not be included the manuscript file.  Try 
not to use abbreviations/acronyms in the précis so that the words are not used up in defining 
them; remember the précis has a 35 word limit. 
 
PRIOR AND REPETITIVE PUBLICATION:  
 The Journal will not consider manuscripts that have appeared, in  par t or in total, in other 
publications, except in special circumstances a pproved by the Editor-in-Chief.  Likewise, 
updates of p reviously published studies that add little data to  an existing publication will not 
be considered. Overlap between patient groups described in serial manuscripts must be 
acknowledged, and references to previous publications that include the same patients must be 
provided. Authors uncertain as to whether or not specific data represent prior or repetitive 
publication should alert the Edit or-in-Chief in the author/ad ditional comments section of the 
submission process and reference copies of the publications in question. 
 
PRECEDENCE 
 Authors who claim precedence for an idea, observation, or therapy are well advised to review 
existing literature thoroughly and also to include an appropriate disclaimer on the cover page 
of the manuscript --"We were unable to find any previous report of this in the literature" or 
"As far as we are aware, this has not been previously reported." Some widely read journals 
might not currently be included in databases, such as that of the National Library of Medicine. 
 
REFERENCES  
Our manuscripts are not intended to be review articles nor do we expect encyclopedic 
referencing.  In keeping with our overall preference for clarity, simplicity and brevity, please 
limit the number of references. Most papers can be adequately referenced with up to 20 to 30 
citations.   Some need 40 or 50; please justify in your cover letter if you find it necessary 












If you use automated reference numbering software or bibliography software, turn it off 
before submitting the manuscript.   
 
1. References section should follow text and begin on a separate page. 
2. Unpublished data, submitted articles, abstracts oral or poster presentations should be             
noted in parentheses within the text 
3. They should be double-spaced and numbered consecutively in order of appearance in 
the text. 
4. In text, designate references by superscript numbers following all punctuation (except 
semicolons).   
5.   If there are 4 or fewer authors, all authors should be listed.  If there are more  
than 4 authors, list the first three and then “et al”. 
6.  Journal abbreviations should conform to those used by the National Library of  
     Medicine (http://www.nlm.nih.gov/tsd/serials/lji.html).  If in doubt as to the correct    
abbreviation, cite the complete journal name. 
7. Include subtitles (Title: subtitle.) 
8.  Use volume numbers. Do not use issue numbers or months unless pagination is not 
consecutive throughout a year. Add (suppl) if supplement. 
9.  Delete digits when in the same range: 231-7 or 1800-27 (NOT 231-237; 1800-1827) 
10. Do not add a discussion to a reference. If the author provides a page range that 
includes discussion break it out as 23-5, discussion 26-8. 
11. Suffixes such as Jr, Sr, and III follow authors’ initials: Wilson JA Jr, or  
       Boxer Wachler M III. 
12. No periods between journal title and year published. 
13. No period in use with initials anywhere. 
14. No spaces after colons and semi-colons in date;vol:pages. 
15. Use italics for gene, genotype, and locus symbols and animal genetic terms 
16. Each reference should end with a period. 
17. Software references depend on the context in which they are mentioned, please refer to 
the Reference Format Examples below for more detailed information. 
 
List only references that you have read and that are pertinent to the manuscript.  For reference 
formatting examples, please go to the Reference Format Examples below.   
  
Cite only published studies as references.  Any references (including books or articles) that 
have been accepted for publication, but not yet published, should have the term “in press” in 
the reference in place of volume and page numbers.   These should be updated prior to 
publication, if possible.  
 
References used in tables and figures should be numbered sequentially, in order of their first 
mention, and listed in the main reference list at the end of the manuscript.  In other words, 
number the references in a table or figure at first mention of the table/figure just as if they 
were the next reference in the text and list them in the main reference list.  If a reference to be 
used in a table or figure was used previously in the text, use the previously assigned number 
in the table/figure. 
 
This includes online only tables and figures.  Since these tables and figures are accessible at 
the end of the manuscript to which it relates, the manuscript’s main reference list is 












A signed permission letter must accompany reference to a “personal communication.” The 
comment should be cited within parentheses in the text. (Smith R, personal communication, 
1992). 
To expedite processing, if asked to revise your manuscript, you will also be asked to provide a 
photocopy of the title page (that include publication information—journal name, vol. year, 
page numbers) of any work cited that was published prior to 1970 in the United States.  The 
same will be requested for all work cited that was published outside of the United States 
regardless of year.  Also include for any books referenced, the book’s copyright page and the 
first page of any chapters referenced.  Although not required upon first submission, it is 
strongly suggested that you make copies of these items during the researching of the 
manuscript so they are readily available if needed.  
Reference Format Examples:  
ABSTRACTS AND UNPUBLISHED DATA, LECTURES, POSTERS, ETC. 
Published abstracts and unpublished data must be cited within parenthesis in the text 
Abstract:  (Invest Ophthalmol Vis Sci 28 [Suppl]:54,1989)   Data:  (Jones, unpublished data) 
Unpublished presentations, posters, and lectures should be cited within parenthesis in the text. 
Cite in text:  (Smith  AB. Quality of life after LASIK. Paper presented at: AAO Annual 
Meeting, November 15, 2002; New Orleans).   Once published, they should be treated as a 
regular reference for a book, journal etc. as shown below.   
JOURNAL ARTICLES 
Journal: 
Davis JT, Allen HD, Powers JD, et al. Population requirements for capitation planning in 
pediatric cardiac surgery. Arch Pediatr Adolesc Med 1996;150:257-9. 
With no volume #: 
Taulbee P. Maryland Quality Project puts new focus on processes of care. Rep Med Guideline 
Outcomes Res. June 1994;10-1. 
Supplements: 
Davis JT, Allen HD, Powers JD, et al. Population requirements for capitation planning in 
pediatric cardiac surgery. Arch Pediatr Adolesc Med 1996;150(suppl):257-9. 
In Press (accepted by a journal): 
Davis JT, Allen HD, Powers JD, et al. Population requirements for capitation planning in 
pediatric cardiac surgery. Arch Pediatr Adolesc Med. In press. 
A discussion: 
Allo MD. In discussion of: McKindley DS, Antibiotic pharmacokinectics following fluid 
resuscitation from traumatic shock. Arch Surg 1994;272:1825-31.  
Foreign titles: 
Please provide English titles whenever possible. When a translation is not printed from the 











Kolmos HJ. Antibiotika i almen praksis [Antibiotics in general practice]. Ugeskr Laeger. 
1996;158:258-60. 
 
When a translation is printed on the published article or in PubMed: 
Kolmos HJ. Antibiotics in general practice [in German]. Ugeskr Laeger. 1996;158:258-60. 
 
Journal available only online: 
Hussain N,  Clive J,  Bhandari V. Current incidence of retinopathy of prematurity, 1989-1997. 
Pediatrics [serial online] 1999;104:e26. Available at 
http://www.pediatrics.org/cgi/content/full/104/3/e26. Accessed July 12, 2002. 
  
Letter: 
Davis JT, Allen HD, Powers JD, et al. Population requirements for capitation planning in 
pediatric cardiac surgery [letter]. Arch Pediatr Adolesc Med 1996;150:257-9. 
 
Study Groups:  
Please cite authorship as seen on published article, not on PubMed.  
Cite study group as author if no individuals are named, or after individual named authors, 
following et al if necessary. When authors listed: 
Crist WM, Garnsey L, Beltangady MS, the Intergroup Rhabdomyosarcoma Committee.  
Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma 
studies I and II. J Clin Oncol 1990;8:443-52. 
 
No authors listed other than the study group: 
Fluorouracil Filtering Surgery Study Group. Fluorouracil filtering surgery study: one-year 
follow-up. Am J Ophthalmol 1990;109:613-6. 




Miller NR. Walsh and Hoyts Clinical Neuro-Ophthalmology. Baltimore, MD: Williams & 
Wilkins; 1991:xx-xx. (include specific inclusive pagination for material being referenced) 
 
Article or chapter in book: 
Hollis S, Rozakis GW. Complications, special cases and management. In: Rozakis GW, ed. 
Refractive Lamellar Keratoplasty. Thorofare, NJ: SLACK Inc.; 1994:111-22. 
 
Edited book: 
Letheridge S, Cannon CR, eds. Bilingual Education: Teaching English as a Second Language. 
Vol. 1. 3rd ed. New York: Praeger; 1980:xx-xx. 
 
Article in edited book, reprint from another source: 
Sluzki CE, Beavin J. Symmetry and complementarity. In: Watzlawick P, Weakland JH, eds. 
The Interactional View. New York: Norton; 1977:711-30. Reprint from: Acta Psiquiatr Psicol 
Am Lat 1965;11:321-30. 
 
Proceedings published as a book: 
Chaddock TE. Gastric emptying of a nutritionally balanced liquid diet. In: Daniel EE, ed. 
Proceedings of the Fourth International Symposium on Gastrointestinal Motility. Ames, IA: 
Mitchell Press; 1974:83-92. 
 











College Bound Seniors. Princeton, NJ: College Board Publications; 1979:xx-xx. 
Several volumes in a multi-volume edited work: 
Wilson JG, Fraser FC, eds. Handbook of Teratology. Vol. 1-4. New York: Plenum Press; 
1977-88. 
English translation of a book: 
Luria AR. The Mind of a Mnemonist [Solotarof L, trans]. New York: Avon Books; 1969:xx-
xx. [original work published 1965]. 
URL (ELECTRONIC CITATION)
Whenever possible, if resources are available online (that are identical to the referenced 
printed version) we provide the URL for the resource in the reference.  We ask that you 
provide a date of online access informing readers that as of that given date the link was still 
live.  
This date can be either the date you accessed it for your research or the date you verified it 
was still a live link.
Health Care Financing Administration. 1996 statistics at a glance. Available at: 
http://www.hcfa.gov/stats/stathili.htm. Accessed December 2, 1996. 
SOFTWARE 
If context is to mention-of-use of software only (mentioned in passing) then cite manufacturer 
and manufacturer location parenthetically in text after first mention of  software, e.g. Epi Info 
(Centers for Disease Control, Atlanta, GA).  
If software is the subject of the report, cite in main reference list: Epi Info [computer 
program]. Version 6.0. Atlanta, GA: Centers for Disease Control and Prevention; 1994. 
Citing software manual  
Software Manual cite in references:  Dean AG, Jean JA. Epi Info, Version 6: A Word-
processing Database. Atlanta, GA: Centers for Disease Control and Prevention; 1994:xx-xx. 
GOVERNMENT DOCUMENTS
Klein R, Klein BE. Beaver Dam Eye Study. Manual of Operations (Revised). Report for 16 
Jun 87 - 31 May 92. Springfield, VA: US Dept of Commerce; 1991:xx-xx. NTIS Publication 
PB91-149823. 
REJECTION OF MANUSCRIPTS 
By Other Journals 
Rejection by another journal will not compromise a review by Ophthalmology. Authors are 
encouraged to inform the Editor-in-Chief of rejection by another journal in the additional 
comments section of the submission process and to include copies of the previous review 
commentary and author responses.  
Appeals Regarding Manuscripts Rejected By Ophthalmology 
Any appeals regarding rejected manuscripts must be made by the corresponding author to the 
Editorial Office by email prior to resubmitting the manuscript.  DO NOT RESUBMIT UNTIL 











“Initiating Rebuttal”).  THIS ASSURES THAT YOUR MANUSCRIPT IS PROCESSED 
UNDER THE SAME MANUSCRIPT NUMBER, KEEPING THE HISTORY TOGETHER. 
Occasionally, you may be told by the Editorial Office that a manuscript is rejected but the 
option to reformat and resubmit it as a letter is suggested.   This can only be done at the 
Editor’s discretion.  If you decide to reformat your paper as a letter, you should send it as a 
new, separate submission. In these scenarios only, WHEN UPLOADING, USE THE “MS TO 
LTR” SELECTION AS THE TYPE OF SUBMISSION.  Also be sure in the “Additional 
Comments” section to advise us of the manuscript number of this original paper you are 
reformatting so we can make reference to it if necessary.   All other Letter to the Editor 
guidelines (700 words, double-spaced, etc) apply including the need for a copyright and 
ICMJE conflict of interest forms to be uploaded.    
REPRINTS
A reprint order form will either be e-mailed or accompany your copyedited manuscript and 
page proofs. You must return this form to the publisher with your corrected page proofs, 
whether or not you order reprints. The cost of reprints increases significantly if they are 
ordered after the initial print run. Reprints, except special orders of 100 or more, are available 
only from authors. 
REVIEW AND PUBLICATION PROCESS   
It is the corresponding author’s responsibility periodically to check on the status of their
manuscript. An email with a decision will be sent and instruct the corresponding author to go 
to the online submission site if a revision is warranted.   
Each m anuscript subm ission will be acknowledge d in the order received in the Editorial 
Office.  The acknowledgm ent letter will note the num ber assigned to the m anuscript. All 
subsequent inquiries about the manuscript must indicate the manuscript number.   Usually two 
and sometimes several reviewers will pa rticipate in the rev iew of a manuscrip t.  The Journal 
does not r eveal th e ide ntity of  its r eviewers but does send  pertinent co mments back to the
corresponding author.  Re-review may be required after revisi on if, in the judgment of the 
Editor-in-Chief, suf ficient m odification of  the manuscript or data just ifies another review 
cycle or if one (or both) of the reviewers requested to see the revision. Point by point response 
is required to the review ers’ comments.  It is ho ped that authors will up load two versions of
the revised manuscript – one clean copy and one showing track changes. 
Once a pap er is accep ted based on  scien tific c ontent, a “P reliminary Acceptance” letter is 
generated. This means that the Editors have accepted your paper for publication and it will 
now process through final form at and reference checking.  Once returned from  the reference 
checker, an other em ail will advise  that eith er there are s ome f inal ref erence, ed itorial or  
format issues for you to addres s or that the m anuscript is co mplete, accepted and has been 
forwarded on to the publisher.   
If the submission is accepted, the correspond ing author will receive typeset page proofs 
online. Each corresponding author is expected to proofread all pages ca refully and answer 
all queries posed by the copy editor. Page pr oofs should be reviewed by m ore than one 
person. All page proofs must be returned to the publis her within 72 hours of receipt to avoid 
delay in publication. The publisher does not se nd reminders; responding to the publisher with 
responses to author queries  and requested changes is the corresponding author’s 











Any appeals regarding rejection  of a manuscript must be m ade by the corresponding author to 
the Editoria l Of fice by em ail prior to resubm itting the m anuscript. DO NOT RESUBMIT 
UNTIL THE ORIGINAL MANUSCRIPT IS R ELEASED BACK T O YOU.  This is known  
as initiating rebuttal and is also done via email to the corresponding author.  THIS ASSURES 
THAT THE MANUS CRIPT IS PROCESS ED UNDE R THE  S AME MANUSC RIPT 
NUMBER, KEEPING THE HISTORY TOGETHER. 
SUBMISSION OF REVISED MANUSCRIPTS 
If asked to revise your m anuscript, an em ail that contains  the revise decision as well as the 
reviewers and/or editor comm ents will be re ceived by the correspond ing author.  Log into 
http://ees.elsevier.com/ophtha/ with your usernam e and passw ord and click on the author 
button.  The m anuscript will be in the auth or m enu under  “subm issions needing revision”. 
Separate files can be accessed by clicking on the “ download files” button.   It is m uch easier 
to work from the “downloadable files” than to work from “view submission”. 
To submit a revised manuscript, first make changes to the text, figures, etc. in the files that you 
downloaded onto your computer from the website. These will have the conte t of what was sent 
to the journal office as original submission.  “View files” is the best access to individual files 
versus “View submission” which only generates a PDF view. 
In the “revise” notification email there may be mention of our having added to the submission a 
PDF file with editors track changes or comments. This can be found by logging in as author, 
locate the specific submission and under action items you will see “manage review attachments.”  
This link will give you access to the mentioned editor track changes.  Sometimes this is a full text 
document and sometimes only the pages that got comments, depending on the editor.  
Review the PDF and, as appropriate, make changes to the appropriate files based on these 
comments as well as editors, reviewers or journal office comments. Save two versions of the 
manuscript file –one showing track changes and the other a clean one with all changes accepted. 
When all files are revised as needed, go to http://ees.elsevier.com/ophtha/, log in as an author. 
Under "Revisions" select "submissions needing revision" and click on "submit revision".   
Step by step instructions will guide you through uploading the revised files in place of the old 
ones. Briefly, in the attach files section there is a listing with check boxes on the right side for 
files for a resubmission. Unclick any of those which will be replaced with the revised version 
recently made on your computer. Leave the boxes checked for those files where no changes from
the original submission are needed. For example, a précis often does not change during a revision 
so that would remain checked and the computer will use the file from the original submission and 
automatically put the file into the revised version. However, the manuscript file has changed and 
by un-checking the box the space is being emptied allowing the revised version to be inserted at 
the next step.   
Click "next" to move forward unchanged files and get to the step that will allow you to load your 
revised files. The attach files screen will give you the opportunity to upload the files to which 
changes were made.  The files that remained checked will be forwarded from the original 
submission and be included in the revised PDF.  
The point by point response (which should list each comment followed by a response for each 
reviewer or editor) should be uploaded as the Point by Point Response. The response should 
explain where changes were made in the text or figures and why, or a defense of your 











A final opportunity is provided to review the completed revised version, with all its files, 
before clicking the final button “submit to journal office.”   Be sure to read and acknowledge the 
Ethics in Publishing before your final submit. 
IF FOR ANY REASON YOU DECIDE NOT TO REVISE YOUR MANUSCRIPT AND NOT 
TO FURTHER PURSUE PUBLICATION IN OPHTHALMOLOGY, BE SURE THE 
CORRESPONDING AUTHOR LOGS INTO THE SYSTEM AND SELECTS THE “DECLINE 
TO REVISE” BUTTON. 
REMEMBER:  
1)  Point by point response  is required to editor and reviewers comments as well as u ploading (if
not done with initial subm ission) copyrights and ICMJE conflict of interest form s from  all 
authors.  Do not just resubm it files that were changed but an entire subm ission.  If the only file 
you had to  change was y our manuscript file –  do upload that new vers ion but when transm itting
to the editorial office include all the other files that make up your com plete submission from the 
previous version.  This is explained at the first step within the submission system.  
2)  Referen ces  At first revision (and if you don’t see a file called “manuscript after reference 
check)  we ask that you take this  opportunity to review the refe rence format style guide and be
sure your references are in the correct format for Ophthalmology.  
To expedite processing, if asked to revise your manuscript, be sure to provide a photocopy of the
title page ( that inc lude publica tion inf ormation-journal name, vol. year, page num bers) of any 
work cited that was published prior to 1970 in the United States.  Also submit the title page for all 
work cited that was published outside of the Unite d States regardless of year and include for any 
books referenced, the books copyright page and the first page of any chapters referenced.  These
can be loaded in a copyright type file titled reference photocopies. 
Often at final acceptance stages, the most recent manuscript file submission in the downloadable 
files section is in a file called “manuscript after reference check.”  This is the same exact file as 
you sent us but the reference checker has gone through your references and made changes as 
needed and possibly added some author queries for you to address.  Generally we shall accept the 
mandatory format changes entered by the reference checker prior to returning the file to you and 
leave only author queries for your response.  If you have duplicate references or for any other 
reason need to renumber the references and hence the text, we ask that you do this to be sure it is 
done correctly – only you have the detailed knowledge to do this correctly.   
3) Figures  Please note any changes to figures in the point by point response letter.
If applicable, the revision decisi on letter will provide direction to prepare your figures to m eet 
specific artwork guidelines for the publisher. If  you cannot m eet these guidelines, contact the  
editorial of fice bef ore submitting your rev isions.   If  ther e are colo r f igures in th e submission, 
please state in your point by point letter that you understand and agree to the following:  
The journal provides one free page of color per first author per year. 
Any additional images will be charged to the authors starting at $650. 
In order to save money on color costs you have a few options:  
a) crea te a com posite (multiple f igures on a single page –  usually not m ore 6 f igures).











the image.  Also be su re to iden tify each picture (e.g.  A, B, C) with  a correspond ing 
legend.  
b) convert the im ages to grayscale (e.g. bl ack and white) assum ing the inform ation that 
you are communicating with this figure would still be evident in black and white.
c) convert some figures to “o nline only supplemental material”.  If  you choose option C 
you need to insert into the text  at the first mention of  the supplemental figures “(available
at http://aaojournal.org)” and well as a m ention on the c over page of which figures are to 
be online only supplemental materials
The publisher can m ake composites but is apprehensive about reducing or cropping im ages. The 
authors (perhaps with the help of a professional), on the other hand, can creatively reduce and 
crop images to best communicate the information, e.g. some authors can fit as many as ten images 
per 8.5 x 11 print. These changes can only be made during the revision and review process.  
Occasionally, despite our best efforts, formatting requirements may lead to illustration placement 
on more than one page by the publisher 
If a manuscript has been reviewed and accepted with color photos, it must be published with color
photos. The author is responsible for page charges for color photos that occupy more than one
page, and cannot opt to have them printed in black and white.  
If you would like to remove, make a composite, or convert any of your images to black and white, 
revision is the only  time to do so. The criterion generally used is whether color illustr ation is
imperative to conveying the inform ation being illu strated.  Y ou can also have non-critical color 
figures, charts or tables put online as  online supplemental materials, at no cost.  These would be
noted within your text, not printed in the  journal and available online.   Refer to figures  for
acceptable figure formats. 
4.   Authors  As with the original subm ission process, you will be prom pted to review your title, 
type, authors, and abstract. Make changes as needed and  save; if no changes are required hit 
"next". Any changes to authors (including order) must be explained in the point by point letter 
and be accompanied by a new copyright. If anyone is being deleted, a letter with their 
acknowledgement of this removal should also be provided in the copyright file.  
STATISTICS
Statistical methods must be identified in table footnotes, illustration legends, or text 
explanations. Software programs used for complex statistical analyses must be identified to 
enable reviewers to verify calculations. For manuscripts in which the study conclusions infer 
equivalency in treatment effect, a sample size calculation and power analysis should be 
included. Levels for alpha and beta errors should be clearly stated in the Methods section of 
the Abstract and text. Authors should state the clinically significant difference that was used 
to determine the power calculation.   The Journal strongly advises statistical consultation 
about data collection and analysis. 
STUDY DESIGN SCHEMES 
As part of the Structured Abstract, authors are required to describe the design of their study.  The 
specific designation of a “study design” serves several purposes.  It forces authors to give careful 
thought to what they have actually done, it provides an important shortcut for editors and 
reviewers to use in categorizing the submission, and it provides the busy reader with a useful 











The Worksheet (modified CONSORT agreement) for randomized controlled trials has been 
required since 1996 and is available online.  The chart below provides basic information 








Reporting observation on a single patient? 
 
CASE REPORT  
Reporting observations on multiple patients, 
with similar findings, or treated in a similar 





Comparing observations or results on similar 
patients who have been treated in more than 







Comparing previous exposure(s) between a 
group of patients with a given disease or 
outcome and a group without the given 
disease or outcome? 
   
*CASE-CONTROL STUDY  
Determining the prevalence of a symptom, 
sign, or disease in a group of individuals or 
examining associations between factors at 







Reporting on a group of individuals with 
defined characteristics before developing a 
condition or undergoing a procedure, and 
then observing them over time for the 
appearance of a disease or surgical result or 
complication. 
  
COHORT STUDY  
Reporting the results of a clinical 
experiment, that you have registered with 
clinicaltrials.gov, or a similar database, in 
which defined groups of subjects receive 
different treatments, placebo, or no 
treatment?   
 
CLINICAL TRIAL Randomized, non-
randomized, masked, 
multicenter 
Evaluating a diagnostic test or comparing 
more than one diagnostic test? 
EVALUATION OF 











No human subjects studied (only tissue, 
biopsies, animals)? 
 
EXPERIMENTAL STUDY  
Reporting the available data addressing a 





Reporting on a phase 4 open-label study, a 
registry or surveillance system, or an 
administrative database?  
DATABASE STUDY  
*Case-control study design must meet these criteria.  If you have simply compared a group of 













Tables require substantial space; please give careful consideration to  the number of tables 
submitted.  The information should not be extensively reiterated in  the text.  Place the 
information in the text or in a table but not both.  
Each table must be titled and num bered consecutively as mentioned in the text. Each colum n 
must have a heading. Term inology used within ta bles should be able to stand independently, 
without the requirement of explanation from the text. Use abbreviations and acronym s only if 
imperative for reasonable table formatting. All abbreviations and acronyms must be explained 
in the table legend. Please do not type more than one table per page.  References for tables 
should be included in the main reference list. If unpublished data or abstract need to 
referenced in a table, place it as a footnote. 
TRANSLATIONAL SCIENCE REVIEWS
In 2010, the Journal launched an exciting new section to bring information about translational 
advances that are on the cusp of widespread clinical application to the readers This is 
primarily a “by invitation only” submission type, however if you have suggestions for topics, 
please contact Jayakrishna Ambati (jamba2@email.uky.edu), the Editor for this section.  
Manuscripts should discuss important current preclinical topics of direct relevance to clinical 
ophthalmologists. The goal is to provide authoritative and cutting edge reviews of topical 
state-of-the-art basic research that is expected to have broad clinical impact in the next few 
years.  For example, in the years prior to the FDA approval of anti-VEGF drugs to treat 
neovascular age related macular degeneration, an article in this section might have 
summarized the relevant basic research that supported Phase I human studies for anti-VEGF 
drugs that are now widely used in the clinic. Manuscripts should be broadly accessible as the 
intended audience includes ophthalmologists with focus mainly, and in some cases solely, on 
clinical practice. Please avoid jargon and do not assume that laboratory techniques will be 
understood by all readers.  
Format is as follows:  
Abstract:  An unstructured abstract of no more than 250 words should be included.   
Text:  The text should be in the range of not more than 20 typed, double spaced, line 
numbered manuscript pages with six tables/figures maximum. Figures and Tables should be 
in files separate from the manuscript and meet the same size and quality criteria as regular 
manuscripts.  The manuscript file includes the cover page, abstract, text and references.     
Structure of text:  Structure for the actual text should be in three sections.  Beginning with a 
section called Background/Introduction, where the problem being addressed by the 
technology is outlined, and then a free form section(s) on the Data, followed by a final section 
called Clinical or Translational Implications.  References should not be encyclopedic (30 
maximum) but should focus on key manuscripts and those of direct clinical relevance. 
Every author must sign a copyright form(s) as well as conflict of interest form(s) which 
should be included with the uploaded files preferably at initial submission but no later than 
first revision.  Every author should also complete an Authorship Criteria Form and submit it 
to the corresponding author.  These forms should not be uploaded unless requested by the 
Editor.   
Like all submissions, whether solicited or not, Translational Science Reviews shall undergo 
rigorous peer review and acceptance is not guaranteed.  Ideally, we would like to have your 











TYPES OF SUBMISSIONS  
Choose from one of the following types for your submission:  
           Manuscript –  general manuscripts which don’t fall into any of the following categories. 
AAO Meeting Paper – manuscripts written that have or will be presented at an American 
            Academy of Ophthalmology Annual Meeting as poster or presentation.   
Ophthalmology always has right of first refusal on these manuscripts. 
Evidence Based Study – manuscripts submitted which are the results of evidence 
            based studies and have additional and some different requirements than those of general 
            manuscripts 
           (see Additional Guidelines for Evidence-Based Manuscripts.) 
AAO Product – results of Academy functions such as Ophthalmic Technology 
Assessments orjoint papers with other academies; only generated by the AAO directly 
Editorials – papers written at the request of the Editor on specific topics.
Letters to the Editor and Replies to Letters – commentaries and critiques by readers of 
various articles, often with responses from authors.  The format and limitations of a 
letter also apply to “MS to LTR” format which is reducing the content of a manuscript 
to a letter and is only used when offered as an option by the Editor-in-Chief. 
Translational Science Reviews – submissions about translational advances that are on 
the cusp of widespread clinical application to the readers; this is primarily “by invitation 
only”. 
USERNAME AND PASSWORD 
The Elsevier Electronic System (EES) that is used for the processing of all submission items 
hinges on correct e-mail addresses for all authors and reviewers within the system. Your 
username and password is the same regardless of your role as author or reviewer.   
Duplicate registrations create serious problems.  Please follow, according to your needs, 
the steps below to update this important information. Be sure to save any changes by 
clicking “update” or “submit” as appropriate before exiting 
IF YOU KNOW YOUR USERNAME AND PASSWORD:
1.  Log into the home page (http://ees.elsevier.com/ophtha/) using your user name and 
password and HIT ENTER.  Do not choose a role button.  
2. Click on “change details” (top of screen) and review your contact information It is
generally easier to use the full page view for this listing.
The preferred method of contact must stay as e-mail for everyone.  If you wish you 
can list two current e-mail addresses as long as you separate them by a semi-colon 
(e.g., home and office e-mail).  If you agree, be sure “Are you available to review?” at 
the bottom of the page is checked off as “yes.”  
Here you can update ALL your most current contact information as well as your “Personal 
Classifications” which are your areas of expertise.  If you scroll down this page and click 
on the personal classifications link, you can mark your correct areas of expertise so we can 
more accurately direct manuscripts to you for review.  BE SURE TO HIT SUBMIT 
before closing window so changes made are saved. 
Taking the time to provide both of these updates will have significant repercussions 











a) stream line reviewer queries by sending you only relevant requests to review which
likewise reduces the turnaround time and gets timely decisions back to authors.
b) to maintain non-biased, quality reviews by knowing who is at which
institution/organization (we avoid using reviewers from the author's
institution/organization.)
c) with updated emails, we can contact you in a timely fashion regardless of your role
as author, reviewer or editor.
3. Change data as needed – Be sure to click “update” on the bottom of the page.
WE GREATLY APPRECIATE YOU TAKING THE TIME TO UPDATE 
YOUR INFORMATION! 
IF YOU DO NOT KNOW YOUR USERNAME AND PASSWORD BUT BELIEVE YOU 
ARE IN THE SYSTEM: 
4. Log into the home page (http://ees.elsevier.com/ophtha/)  
5.  Click on “register” (at top of screen) and fill in your first name, last name and e-
mail address.  If you are already in the system it will offer to send your username and 
password to your e-mail address.  When you receive it, follow the directions #2 and #3 
above. 
6.  If you have moved within the past year, we suggest you also try putting in your 
previous e-mail address so that you do not generate duplicate registrations within the 
system.  If your old e-mail is in the system (and it is still accessible to you) click on 
“register” and follow the steps in #5 above. 
IF YOU HAVE NEVER REGISTERED BEFORE IN ANY ROLE: 
7.  If you have never been in the system in any role (author or reviewer) go to the 
home page at http://ees.elsevier.com/ophtha/  click on register and follow the steps 
provided at the website. 
If for any reason you c annot access your information or are not sure if you are in the system,
please send an e-mail to vdoyle@jhmi.edu  with your first name, last name, city and state or city 
and country as appropriate and your new e-mail address.  The Editorial Office will update your 
information and then send you an e-mail with your user name and password so you can log in and 
access your contact data and personal classifications and update as needed.
VIDEO CLIPS  
If you opt for to submit a video as an online supplement, add a reference to it in parenthesis at 
an appropriate place within the text of the manuscript.  Also, add a statement to the title page 
that should read similar to: “This article contains a video as additional online-only material. 
The following should appear online-only: Clip 1, Clip 2 and Clip 3” Obviously, the materials 
can not appear in the printed version but will be archived with the online version on the 
publisher’s website http://www.ophsource.com/periodicals/ophtha and accessible through 
Medline and other online databases.  
We do not have video editing software, but a website with useful tips on reducing file size can 











1. Maximum: 8 minutes total. We recommend several smaller clips that total no more than
8 minutes.
2. Size: no larger than 10 MB for each file
3. File extension types: .MPG (MPEG-1 or 2), .AVI, .MOV
4. Audio commentary, describing what is bein g shown is highly recommended. Do not 
use copyrighted music.
5. Within the subm ission, there m ust be a br ief legend describing the contents of the 
video and the indicating the viewing order.
6. Video files should be loaded with your submission into the Electronic Subm ission
System. File names should correspond to video legends.
7. On the title page add: “This manuscript contains (number) video clips.
8. Load them into your submission using the “multimedia” file type
C. DOWNLOADABLE FORMS
All forms, except for the Study Design Worksheet, allow you to type in the required information 
and save as files to your desktop. Copyrights can be filled out online but will need to be printed 
out 
for original signatures. Signatures must be original, electronic signatures are not acceptable. 
ICMJE and copyrights should be uploaded at the time of your submission. 
The copyright and conflict of interest disclosure forms WILL NOT appear as full text but rather 
only as a link in the PDF that you approve after you’ve uploaded them. This is so the transmitted
file will be as small as possible for transmittal to reviewers and editors.
AUTHORS
Authorship Criteria Statement 
Copyright Assignment Form 
ICMJE Conflict of Interest Form (COI form) 
REVIEWERS
CME Credit Request for Manuscript Review  
OTHER 
Consort Agreement is mandatory for a Randomized Controlled Trial  











D.  MISCELLANEOUS INFORMATION  
 
1.  Developing a Manuscript 
Authors are well advised to plan for eventual publication early in the conduct of their 
research, including the choice of journal and the order of authorship.  The most current 
Guide/Instructions for Authors for the intended journal should be obtained and read carefully 
in preparation for eventual manuscript submission.  The order of authorship, assuming more 
than one individual is involved, should be established by mutual consent early in the 
manuscript preparation process to avoid subsequent conflicts.  In rare instances, authors ask 
for changes in authorship after submission and do not agree themselves what they want.  In 
such cases, the Editor will withdraw the manuscript from consideration and allow the authors 
to resubmit once they agree, with new and correct copyright transfer forms.  For 
Ophthalmology, a listing as an author implies a substantial intellectual contribution to the 
conduct of research and preparation of the manuscript (see Guide for Authors regarding 
authorship, group authorship, and acknowledgments). 
 
Clinical or basic science investigations must be designed (planned) properly and executed 
rigorously to permit meaningful analysis of resulting data.  Appropriate study design experts, 
biostatisticians, or other advisors as indicated should be incorporated in both the initial 
planning and/or the authorship for all research publications. 
 
It is strongly recommended that you plan the research, obtain appropriate IRB and or 
regulatory approval, do the research and then write the manuscript. In other words, 
prospective research is favored. 
 
A.  Ophthalmology’s Study Design Scheme 
 
As part of the Structured Abstract, authors are required to describe the design of their study.  The 
specific designation of a “study design” serves several purposes.  It forces authors to give careful 
thought to what they have actually done, it provides an important shortcut for editors and 
reviewers to use in categorizing the submission, and it provides the busy reader with a useful 
capsule of the type of study that was performed.   
 
The worksheet (modified CONSORT agreement) for randomized controlled trials has been 
required since 1996 and is available online.  The chart below provides basic information 
regarding the direction we are heading with the new designs.   
 




Reporting observation on a single patient? 
 
CASE REPORT  
Reporting observations on multiple 
patients, with similar findings, or treated 






Comparing observations or results on 
similar patients who have been treated in 
more than one way?  Comparing a treated 
















Comparing previous exposure(s) between 
a group of patients with a given disease or 
outcome and a group without the given 
disease or outcome? 
*CASE-CONTROL
STUDY
Determining the prevalence of a symptom, 
sign, or disease in a group of individuals 
or examining associations between factors 






Reporting on a group of individuals with 
defined characteristics before developing 
a condition or undergoing a procedure, 
and then observing them over time for the 
appearance of a disease or surgical result 
or complication. 
COHORT STUDY 
Reporting the results of a clinical 
experiment that you have registered with 
clinicaltrials.gov or a similar database, in 
which defined groups of subjects receive 
different treatments, placebo, or no 
treatment?   
CLINICAL TRIAL Randomized, non-
randomized, masked, 
multicenter 
Evaluating a diagnostic test or comparing 








No human subjects studied (only tissue, 
biopsies, and animals)? 
EXPERIMENTAL 
STUDY 
Reporting the available data addressing a 





Reporting on a phase 4 open-label study, a 
registry or surveillance system, or an 
administrative database?  
DATABASE STUDY 
*Case-control study design must meet these criteria.  If you have simply compared a group of
cases and selected a control group, the design is most likely “Comparative case series”.
B. Literature Review
A thorough review of available literature with appropriate data bases (Index Medicus, 
PubMed, MEDLINE, Cochrane Central Register (Cochrane Library), EMBASE, 
LILACS, etc.) is mandatory during the planning phases of a research project to avoid 
unnecessary duplication of effort and errors in acknowledging credit due others.  
When you allude to your interpretation of the previous literature, e.g., “we report the 
first case of …” in the methods section or discussion section be sure to explain the 











when the search was undertaken, and whether any more than a basic computer search 
was conducted.  Non-English literature should be included with help from library 
resources as necessary. Ophthalmology requests that authors include only essential 
references that relate directly to the work being reported and that they verify their 
accuracy. Refer to references for formatting of various types of references. 
 
To expedite processing, if you are asked to revise your manuscript, you will also be 
asked to provide a photocopy of the title page (that include publication information—
journal name, vol. year, page numbers) of any work cited that was published prior to 
1970 in the United States.  You will also be asked to submit the title page for all work 
cited that was published outside of the United States regardless of year.  Also include 
for any books referenced, the book’s copyright page and the first page of any chapters 
referenced.  Although not required upon first submission, it is strongly suggested that 
you make copies of these items during the researching of your manuscript so they are 
readily available if needed.  
 
C. Organizing Research Data 
 
The Study Design should be defined clearly before data collection is carried out with 
pre-designed forms/methodology to enable proper preservation and eventual analysis 
of data collected, regardless of whether data collection is retrospective or prospective.  
 
D.  Epidemiological and Statistical Considerations 
          
Definitions of relevant terms are provided in the Glossary of Terms. 
 
Generally, statistical tests should be applied appropriately with consideration for 
potentially confounding variables.  P-value and/or confidence intervals should be 
provided as appropriate. 
 
Two key questions should be answered prior to submission of the manuscript: 
 1. Is the information adequate to permit interpretation of the results? 
 2. Are the conclusions justified? 
 
Cautionary notes about terminology: 
 1. Ensure proper use of “procedures” vs. “eyes” vs. “patients” vs. “subjects”. 
 2. Clarify whether or not the “last” follow-up information or a summary of 
“interval”      information is presented.  Interval follow up is preferred.  
               (DiLoreto DA Jr, Bressler NM,    Bressler SB, Schachat AP.  Use of best and 
final visual acuity outcomes in ophthalmological research.  Arch Ophthalmol. 
2003;121:1586-90.) 
 3. Univariate and multivariate analyses are frequently misused in current 
literature. Their appropriateness should be verified by expert consultation as 
necessary. 
 4. P-values are frequently misused. 
 5. “Incidence” describes new cases over some interval of time 
 6. “Prevalence” describes cases at one defined interval in time. 
 7. Remember to distinguish accurately between “standards” and 
“standardized” and “computed” and “computerized” 
 8.  The terms “safety” and “efficacy” are hackneyed and often misused.  
Please review a pertinent editorial on this: Schachat AP, Chambers WA, Liesegang TJ, 











and Effective. Ophthalmology.2003;110-2073-4. 
2. EQUIVALENT VISUAL ACUITY CONVERSION CHART
3.  GLOSSARY OF TERMS 
 adverse event Complication of therapy or disease occurring during a study.  
 analysis  Comparison of study and control groups or examination of outcomes in 
non-controlled studies.  Assessment of data, including primary and secondary 
comparisons of interest. 
 assignment  Designation of individuals as study or control subjects.
 assessment  Determination of the results of the investigation.
 bias  A non-chance event arising from faults in study design or measurement or
data collection.  Bias may prejudice results in that traditional statistical analysis
may be precluded or unreliable.  Bias may be introduced into a study by many
factors including subject selection, follow-up, study factor choice, unmasked
data collection, temporal trends in disease, co-management of disease if not
concurrent in time, ecological fallacy, retrieval methods, play of chance,
publication choice or prejudice of investigators.
 case-control study  An observational (non-interventional, usually retrospective)
study that begins by identifying individuals with a disease (cases) for comparison
to individuals without a disease (controls or reference group), in which analysis











 case series  Case series include those studies describing more than one
consecutive or non-consecutive case, studied retrospectively or prospectively,
usually with regard to the outcome of an intervention for its efficacy, safety, and
complications.  Non-comparative case series generally have no control group
included but outcome may be compared to that in the literature.
 case report  Usually a retrospective report of a single interventional or
observational case experience, often with clinical-pathological correlation.
 clinic-based  Term used to define the population studied derived from a single
clinic population or set of populations
 cohort  A group of individuals (subjects) who share a common experience or
condition.
 cohort study  An observational (usually prospective) study that begins by 
identifying individuals with (study group) and without (control group) a factor 
being investigated to observe over time with regard to disease outcome; study 
and control groups may be concurrent or non-concurrent but must be derived 
from the same well defined cohort;  almost always prospective with regard to 
data collection.  Almost always longitudinal in  that a particular group of patients 
is followed forward from a point in time.  May or may not be population-based. 
 comparative study  Study including two or more defined groups, compared one 
to another, to make a judgment about the influence of some factor or treatment. 
 confounding variables  Risk factors that may affect the relationship between a 
risk factor and an outcome. 
 control group  Reference group or group of individuals similar to treatment 
group except for exposure to study intervention. 
 crossover design  This type of study compares two or more treatments or 
interventions in which the subjects or patients, upon completion of one therapy, 
are switched to the alternative(s).
 cross-sectional study  An observational study that identifies individuals with
and without the condition or exposure being studied at the same time
(synonymous with prevalence study).  May or may not be population-based.
 double-masked study  At the times of data collection and analysis, neither
evaluators nor subjects know which intervention or test is applied.
 ecological fallacy  This term applies to summary data which misrepresent a
relationship within a larger group.  Risk cannot be inferred for an individual
based on group results.
 epidemiology study  Prospective or retrospective observational investigation of
disease or characteristics; ideally according to pre-determined protocol; includes











 experimental study  No human subjects involved.
 extrapolation  Drawing conclusions about the meaning of the study for
individuals or situations not included in the study.
 external validity  A study’s conclusions may be valid only for a specified
external population; (how general are the findings?).
 frequency  The number of occurrences of an event or the proportion of members
of a population or statistical sample falling into a particular class; the number of
occurrences of a periodic or recurrent process per unit time or per sample.
 genetic terminology  Terminology used in genetics manuscripts should conform
to  Human Gene Nomenclature (HGNC) Guidelines. Please visit the HGNC 
website for the most current draft version of the guidelines 
http://www.gene.ucl.ac.uk/nomenclature.  Do not submit scrambled pedigrees.  If 
a scrambled pedigree is required, please correspond with the Editor-in-Chief at 
the time of manuscript submission for a waiver of this policy.    Base sequences, 
such as for PCR primers, should not be included in the text of a manuscript. 
Authors may opt for an online supplement or provide a URL where the primers 
can be found or an email address for interested readers.  Human or animal tissue 
examination employing traditional morphologic methods including light, 
scanning, and transmission electron microscopy. 
 historical controls   A collection of patients used as a comparison group, who 
were identified and treated or observed in the past in a period that predates the 
time covered by other study groups. 
 historical manuscript   A manuscript describing prior events, usually in 
chronological order, or the history of individuals or organizations.  
 incidence  The rate of event or disease occurrence in those at risk in a defined 
population per unit time. 
 internal validity  The observed differences between index and comparison groups
are attributable to the independent variables under study.
 interpretation Drawing conclusions about the meaning of similarities and
differences found between study and control groups or between studies.
 intervention  Manipulation(s), treatment(s), test(s), or observation(s) employed
to generate data for purposes of achieving the study goals.
 interventional study  A study that includes an attempt to alter the course of
disease by medical or surgical or other therapy.
 matched controls Subjects who have specific characteristics similar to cases
(study subjects).  Commonly used matching characteristics include age, gender,











 meta-analysis  Data gathered entirely from existing literature using statistical
methodology to integrate and summarize results of several studies.  The data
from individual studies may be weighted by the degree of variance or other study
characteristics to arrive at a pooled estimate of the relation between a factor and
an outcome.  Usually now applied only to analysis of previously published
randomized controlled trials.
 modifiers  Terms used to specify details about a study: (comparative,
prospective, retrospective, interventional, non-interventional, observational,
randomized, non-randomized, controlled, non-controlled, histopathologic,
experimental, human, non-human, primate, etc.)
 multicenter clinical trial  A clinical (human) trial involving two or more 
clinical centers, a common study protocol, a data center, and a data coordinating 
center, or coordinating centers to receive, process and analyze study data. 
 observational study   No intervention or attempt to  alter the natural course of
disease or physical condition.  
 ocular trauma terminology   Terminology used in descriptions of ocular trauma
should conform to the recommendations of the United States Eye Injury Registry 
and the International Society of Ocular Trauma.  (See: Kuhn F, Morris R, 
Witherspoon CD, et al. A standardized classification of ocular trauma. 
Ophthalmology 1996; 103:240- 3). 
 odds (of an event)  Odds  = # of patients fulfilling endpoint criterion
# of patients not fulfilling endpoint criterion
 odds ratio (relative odds, cross product)   = ad/bc  where: 
Exposed      Unexposed 
         Disease         a                  b 
       No Disease       c                  d 
 phase I, II, III, IV (FDA) [US FDA Classifications: (modifiers) applicable to
new human therapies, including drugs and devices, under consideration for
marketing approval]
 Phase I: Safety and dose testing in humans (usually  without controls) (Studies a
small number of patients to determine tolerated doses [dose escalation] and side
effects for risks of new agents, devices)
 Phase II: Testing of safety (with or without controls) and efficacy (requires
controls) in affected subjects,
 Phase III:  Testing of efficacy and safety (with controls) (randomized controlled
trial) 











 [retrospective, comparative studies of interventions, drugs, devices]
 placebo  An inert (pharmacologically inactive) medication, which lacks a
therapeutically active ingredient.
 population-based  A study including all individuals in a defined geographical
area or otherwise clearly defined subgroup of the population.  A study conducted
on a randomly selected representative group (10%, 20% etc.) of the population at
risk.
 prevalence  The proportion of subjects with a particular disease or condition at a
point in time (best estimate of the probability of disease before performing the
test or intervention).
 prevalent  This term implies a characteristic which is widespread.
 prospective study  Data are collected before and/or after interventions, 
measurements or events by using previously defined protocols. 
 protocol deviation  Departure from the planned sequence of testing, 
interventions follow-up, or analysis during a study. 
 publication bias  Negative studies are unlikely to be published and are less 
likely than positive studies to be available for detailed literature reviews or meta-
analyses.  Studies which duplicate previous studies are also less likely to be 
published. 
 randomized (controlled) trial  A trial (human or non-human) that involves at 
least one experimental treatment group and one control group, concurrent 
enrollment, and follow-up of the test and control groups, and in which the 
assignment to experimental and control groups is by a randomization process.  
Neither the subjects nor the persons responsible for treatment can influence the 
assignments, and the assignments remain unknown to the subjects and staff until 
eligibility has been determined.  
 referral based  The subjects studied are accumulated through an intermediary
(referred).
 relative frequency  The average rate of occurrences of a particular event in a
large number of repeated trials.
 relative risk The Relative Risk (RR) =       risk of disease in treatment group
risk of disease in control group 
 retrieval bias  Retrieval bias may occur when data is not obtained from all
relevant cases or studies.
 retrospective study  Data collected and analyzed after all measurements,











 review  A manuscript which summarizes the scientific history and current
understanding of a topic, procedure, or disease.
 risk  The risk in a defined population and time equals:
# patients fulfilling endpoint criterion 
total # patients 
 sham procedure  A deliberately ineffective intervention.
 single masked study  The subjects or the evaluators, but not both, know which
intervention is applied.
 study size:  (for Ophthalmology Data base Coding)
 (Total number of study subjects)
small series = n < 10 
medium series = 10 > n < 30 
large series = n > 31  
 systematic review  A detailed review and analysis of previously published 
literature.
 triple masked study All participants are masked to the intervention. None of the 
investigators, the subjects, the data and safety monitoring committee, nor the 
biostatisticians know which intervention or analysis is applied. 
4.  Grammar/Language Guide
Good writing supports and augments good research.  Clear, concise language is highly
desirable in scientific communications and consistent with good scholarship.  Sentence 
structure should be grammatically correct and language use should incorporate a reasonable 
breadth of vocabulary.  Obfuscation, circuitous verbiage, and poor logic devalue the 
communication and only i crease the risk of confusing the reader.  Redundancy of text or 
duplication of text points in tables wastes precious space and unnecessarily complicate a 
manuscript.  Authors should plan to do several revisions before submission to shorten and to 
focus an article. Clear writing itself greatly enhances the impact of research findings.  If the 
following does not answer your basic issues, you may wish to submit your paper to an English 
Editor. 
Examples of specific flaws in language use to avoid include: 
a. Passive Voice
Active voice is much preferred to passive voice, which should be used sparingly.  
Passive voice tends to “depersonalize” the subject and remove the author(s) from 
active responsibility (or bias?) for his/her work.  Active voice is generally more 
concise than passive voice and saves space and time.  Passive voice may force the 
reader to stop and think about whom is doing the action.  It does not relieve the author 
of direct responsibility for observations, opinions, or conclusions (e.g., “The problem 
of blood flow was investigated...” vs. “We investigated the problem of blood flow...”; 











found.”  vs. “The swelling subsided gradually and visual acuity returned to normal.”) 
b. Impersonal Passive
Many authors “cheat” the passive voice with weak sentence openers that are literally 
active but functionally passive.  Avoid phrases such as:  “It is...”, “There is...”, “It is 
important to note that...”, “It is essential that...”.  Removing such phrases permits more 
succinct and clear thought.  (e.g., “Although there is evidence suggesting involvement 
of genetic factors, the exact role of such factors and mode of inheritance remain to be 
elucidated fully.”  The same point is stated more clearly as: “The role of genetic 
factors is unknown.”) 
c. Subject/Verb Separation
Remember that a reader can hold the subject of a sentence in his consciousness only so 
long.  Sentences in which the subject sits many words away from its verb may force 
the reader to reread the entire paragraph to understand the thought. For example: “The 
smallest of the URFs (URFA6L), a 207-nucleotide (nt) reading frame overlapping out 
of phase the NH2-terminal portion of the adenosinetriphosphatase (ATPase) subunit 6 
gene, has been identified as the animal equivalent of the recently discovered yeast H+ 
- ATPase subunit 8 gene.” 
In this 41-word sentence, 23 words separate the subject “smallest” from its verb “has 
been identified.”  A possible revision would appear: “The smallest of the URFs 
(URFA6L) has been identified as the animal equivalent of...” 
Keep subjects and verbs reasonably close together. 
d. Abstruse, Obtuse, Arcane, or Numerous Abbreviations/Acronyms
A reasonable balance must exist between the introduction of an unconventional 
abbreviation and the use of the full term.  Many authors tend  to use 
abbreviations/acronyms for any phrase that has two or three words in it, in titles, 
captions, and text.  When these abbreviations/acronyms are multiple and repetitive, 
reading becomes analysis of shorthand.    In general, minimize use of abbreviations.  
Tables and figures need to make sense on their own so readers should not need to click 
back to the main text and search out definitions of abbreviations/acronyms.  
Abbreviations/acronyms need to be defined parenthetically in each figure and in a 
legend for each table.  Similarly, they need to be defined in the précis and abstract 
since there things also need to make sense on a “stand alone” basis.  Abbreviations 
should defined again at first use in the main text.  There is a brief list of 
abbreviations/acronyms that have become “accepted” overtime and these are the only 
ones that do not need defining and the only ones that can be used in titles.   
e. Improper Subject-Verb Agreement
Rules of prescriptive grammar require the agreement of subject(s) and verb(s) in 
person and number and the agreement of pronouns and antecedents in number, person, 
and gender.  Subjects and verbs must agree.   “Data” is always plural. 
 “My own experience and that of my colleagues argue that...”
 “This datum from  this study suggests  that 1000 cGy of ext ernal beam  photon 











 “The linkage data and haplotype data are presented.”
 “The majority of cases is considered to be multifactorial in origin.”
f. Avoid split infinitives
“My mother told me to never split an infinitive.” should be “My mother told me never 
to split an infinitive.” 
g. Non-Agreement of Verb Tenses
The use of both past (or imperfect) and present tenses in the same sentence or 
paragraph can be awkward.  (e.g., “On last examination, her visual acuity is 20/40 and 
further surgery was refused.”) 
Harmonize tenses in a paragraph or presentation. 
h. Redundancies
Repetition weakens a thought or presentation and sometimes can lead to amusing 
results 
 “[Glaucoma] is caused by alterations in the sieve-like trabecular meshwork.” 
 “The entire tumor was excised completely.”
 “For more information, communicate with the Director by writing him at...” 
 “An area encompassing a 2 disc diameter radius centered on the foveal center 
was graded for each eye.” 
 “We examined a large number of patients after a fairly long, and standardized, 
follow-up period.”  
 “The family studied has twice previously been reported in the literature.”
i. Human Characteristics Attributed to Disease Processes
Insensitivity and jargon often cause us to attribute human senses to a disease (e.g., 
“We have no explanation for the tumor’s predilection for younger females.”.) 
j. Circumlocution and Compression (too many words vs too few)
Sometimes, in an attempt to be brief, a compressed thought will yield a bizarre 
statement.  
 “Sudden death from heart block may require early cardiac pacing.”
 “Blood shortages in Houston hit dangerously low levels.”
 “The eye with the more severe pathology was used in patients with bilateral
clinically significant macular edema.”
k. Misplaced Modifiers
When an adjective or adverb directly precedes or follows the word that it modifies, the 
connection cannot be mistaken.  But a modifier in an unusual position may fall into the 
wrong company and f orm an unsuitable attachm ent.  The m omentary m isreading 
distracts from the substance of wha t you are saying.  (e.g., “Forty-five patients were  











Read each sentence and thought carefully and place the modifiers precisely. 
l. Hyperbole of Emphasis
An author can make a point with a powerful word alone. Adding an emphatic 
modifier, an intensive adverb (e.g., very, really, truly, actually, etc.), attenuates the 
phrase and defeats the purpose. It reduces the adjective to conversational pablum, 
depriving it of force.  The repeated superlative or modified adjective indicates extreme 
positions (e.g., “absolutely no justification”, “much more frequently”).   
m. Hyperbole of Thought
Don’t use big words!  Keep it simple versus 
“When promulgating your esoteric cogitative or articulating your superficial 
sentimentalities and amicable philosophical and psychological observations, 
beware of platitudinous ponderosity.  Let your verbal evaporations have 
lucidity, intelligibility, and veracious vivacity without rodomontade or thespian 
bombast.  Sedulously avoid all polysyllabic profundity, pompous propensity, 
and sophomore vacuity.”  
n. The Dangling Participle
Participles, verb forms functioning as adjectives, may detach themselves from the 
formal subject that they should qualify.  In other words, they dangle.  (e.g., “Having 
expressed a direct interest in our institution, we have enclosed the materials that you 
requested with an application form.”)   
The most common and misused dangling participle in medical and scientific literature 
is “using.”  Inexplicably, reviewers and editors have tolerated the admission of the 
dangling participle “using” in text and title.  In these examples, who or what is 
“using”? 
 “Genotyping was performed using a semi-automated fluorescence scanning 
system.” 
 “Linkage analysis was performed using both genetic model-dependent and
model-independent methods.”
 “The present study measured vision using the ETDRS protocol with
standardized refraction.”
 “Patients with useful vision in the fellow eye were treated using a lateral field,
entering at a 45-degree angle, using a 45-degree couch rotation to achieve this.”
Substitute a preposition as appropriate, or rewrite the phrase. 
o. Stating the Obvious
“The development of this tumor probably precedes its clinical appearance.”  Do we 
really need to be so informed? 











“This gene probably plays some role in “run-of-the-mill” glaucoma...” 
Avoid wordy and colloquial expressions such as: 
- a majority of (= most)
- at the present time (= now)
- due to the fact that (= because)
- in the event that (=If)
- it is clear that (= clearly)
- it is suggested that (= I think)
- prior to (= before)
- take into consideration (= consider)
- with respect to (= about)
q. Run-on Sentences
Sentences should be reasonable in length and convey one primary thought or 
relationship. Not presenting several thoughts or relationships in one sentence often is 
confusing and create questionably inter-related concepts. While brief is better, avoid
one sentence paragraphs except in rare circumstances.  Usually, the thought can be 
appended to the preceding or following paragraph. 
r. Spelling Errors
In the modern era of electronic spell checkers, typographical and spelling errors 
should be less frequent.  Remember that spell checkers and grammar checkers have 
their limits and nothing replaces a good, careful final read of  the manuscript. Read the 
manuscript (again!).  Private editing is a good investment.  Even ask a colleague or 
spouse to read the manuscript before it is submitted to the Journal.
s. Its, It’s, and Its’
Its conveys possession.  It’s is a contraction of it is.  Its’ is not in use.  
